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Abstract
Diagnostic strategies for assessing brain pathology include clinical and a para-clinical
documentation, which is supported by imaging of morphological and functional proper-
ties. The pathophysiology of the central nervous system (CNS) can be visualised e. g.
by imaging the biodistribution of a specific radio-pharmaceutical with positron emission
tomography (PET). This work deals with a non-invasive characterisation of CNS lesions
in patients suffering from (1) relapsing-remitting multiple sclerosis (RRMS) or from (2)
a glial brain tumour (glioma). In this context – besides biochemical properties such as
e. g. the (patho-) physiology of the blood-brain barrier (BBB) – methodological aspects
are of paramount importance and will be addressed in this thesis.
First, preliminary phantom measurements were performed, aiming to establish and
evaluate methods for the delineation of focal MS and glioma lesions. For this, var-
ious segmentation methods and the resulting PET signal within lesion volumes were
investigated by performing measurements with a NEMA NU 2-2001 spheres phantom
for varying signal-to-background ratios (SBR), background concentrations, and image
reconstruction algorithms. The ability to reproduce true boundaries was evaluated for
different threshold-based segmentation approaches.
The main goal of the first publication was to establish a reference tissue-based quan-
tification approach – aiming to avoid invasive blood-sampling and long scan durations –
for the assessment of acute RRMS lesions with the novel PET tracer 18F-GE-180, which
targets the 18-kDa translocator protein (TSPO). Besides the occurrence of acute focal
white matter lesions, MS may potentially affect the entire brain especially in progressive
state. A voxel-wise comparison of tissue uptake in RRMS patients and healthy controls
with statistical parametric mapping (SPM) revealed, that frontal cortex (FC) is least
affected by disease, and a normalisation to FC uptake mostly reduced the inter-subject
variability of white matter uptake in healthy controls. A method for the exclusion of
affected voxels from the FC volume was established, yielding a pseudo-reference region
(PRR). The obtained tissue uptake values normalised to the PRR uptake significantly
correlated with parameters from pharmacokinetic modelling. A further characterisation
of MS lesions with texture and shape parameters might enable e. g. a non-invasive dif-
ferentiation of focal MS and diffuse progressive multifocal leukoencephalopathy (PML)
lesions.
In the second study voxel-wise parametric information derived from dynamic 18F-
FET (amino acid) PET images was utilised for non-invasive glioma grading. The ability
to distinguish molecular genetic and histologic glioma grades was assessed for differ-
ent intensity, histogram, texture, shape, and pharmacokinetic modelling parameters.
In univariate analysis the highest accuracy for non-invasive grading was obtained for a
quantification of parameter distributions based on percentage volume histograms (PVH).
Among pharmacokinetic modelling parameters, the most significant differences between
xviii ABSTRACT
grades were found for transfer rates K1 and k2 from 1-tissue compartment model with
blood volume fraction (1TC-VB), k4 from 2TC-VB, and parameters from Patlak plots.
It has been demonstrated, that e. g. static and kinetic parameter maps provide comple-
mentary information, thus enabling the detection of aggressive sub-volumes and tumour
heterogeneity.
The presented results are encouraging and form the basis for future applications in
clinical routine, enhancing the efficiency and accuracy of diagnostic procedures. The
next steps should include a validation of suspected tumour heterogeneity by performing
stereotactic biopsies. This might enable the utilisation of multi-parametric and multi-
modal information for a voxel-wise classification, or an estimation of probability maps
e. g. predicting disease progression or recurrence on a voxel-basis.
Zusammenfassung
Eine diagnostische Beurteilung von Gehirn-Pathologien beinhaltet eine klinische und
para-klinische Dokumentation, welche durch morphologische und funktionelle Bildge-
bung unterstu¨tzt wird. Die Pathophysiologie des zentralen Nervensystems (ZNS) kann
beispielsweise visualisiert werden, indem die Biodistribution spezifischer Radiopharma-
zeutika mit Positronen-Emissions-Tomographie (PET) abgebildet wird. Diese Arbeit be-
fasst sich mit der nicht-invasiven Charakterisierung von ZNS-La¨sionen in Patienten, die
unter schubfo¨rmig-remittierender Multipler Sklerose (RRMS) oder einem glialen Hirn-
Tumor (Gliom) leiden. In diesem Zusammenhang sind – neben biochemischen Eigen-
schaften wie z.B. der (Patho-) Physiologie der Blut-Hirn-Schranke (BBB) – methodische
Aspekte von besonderer Wichtigkeit und werden in dieser Arbeit adressiert.
Als erstes wurden vorbereitende Phantommessungen durchgefu¨hrt, um Methoden fu¨r
die Segmentierung von fokalen MS und Gliom La¨sionen zu etablieren und zu beurtei-
len. Hierfu¨r wurden verschiedene Segmentierungsmethoden und das resultierende PET
Signal innerhalb der La¨sions-Volumina durch Messungen mit einem NEMA NU 2-2001
Kugel-Phantom mit verschiedenen Signal-zu-Hintergrund Verha¨ltnissen (SBR), Hinter-
grund-Konzentrationen und Bildrekonstruktionsalgorithmen untersucht. Die Fa¨higkeit
die wahren Objektgrenzen zu reproduzieren, wurde fu¨r verschiedene Grenzwert-basierte
Segmentierungsmethoden evaluiert.
Das Hauptziel der ersten Publikation war die Etablierung eines Referenz-Gewebe
basierten Ansatzes fu¨r die Beurteilung akuter RRMS La¨sionen mit dem PET-Tracer
18F-GE-180, welcher spezifisch an das 18-kDa Translokator-Protein (TSPO) bindet, wo-
bei eine invasive Entnahme von Blutproben und lange Scan-Zeiten vermieden werden
sollten. Neben dem akuten Auftreten fokaler La¨sionen in der weißen Substanz kann
MS potenziell das gesamte Gehirn beeintra¨chtigen, insbesondere im fortgeschrittenem
Stadium. Ein Voxel-weiser Vergleich der Tracer-Aufnahme in Gewebe bei RRMS Pati-
enten und gesunden Kontrollen mit statistisch-parametrischem Mapping (SPM) ergab,
dass der frontale Kortex (FC) am wenigsten durch die Krankheit beeintra¨chtigt ist und,
dass eine Normierung auf die Tracer-Aufnahme im FC am meisten die Variabilita¨t der
Aufnahme in der weißen Substanz zwischen Individuen reduziert. Es wurde eine Me-
thode zum Ausschluss beeintra¨chtigter Voxel aus dem FC-Volumen etabliert, und somit
eine pseudo-Referenz Region (PRR) generiert. Die mit dem PRR-Wert normierte Ge-
webe-Aufnahme korrelierte signifikant mit pharmakokinetischen Modell-Parametern. Ei-
ne weiterfu¨hrende Charakterisierung von MS-La¨sionen anhand von Textur- oder Form-
Parametern ko¨nnte beispielsweise eine nicht-invasive Unterscheidung zwischen fokalen
MS- und diffusen La¨sionen der progressiven multifokalen Leukenzephalopathie (PML)
ermo¨glichen.
In der zweiten Studie wurde Voxel-weise parametrische Information aus dynami-
schen 18F-FET (Aminosa¨ure) PET-Bildern fu¨r eine nicht-invasive Gliom-Einstufung
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genutzt. Die Fa¨higkeit molekulargenetische und histologische Gliom-Grade zu unter-
scheiden wurde fu¨r verschiedene Intensita¨ts-, Histogramm-, Form-, und pharmakokineti-
sche Modell-Parameter beurteilt. In univariater Analyse konnte die ho¨chste Genauigkeit
fu¨r eine nicht-invasive Klassifizierung durch eine Quantifizierung der Parametervertei-
lung anhand von prozentualen Volumen-Anteil-Histogrammen (PVH) erreicht werden.
Fu¨r die pharmakokinetischen Modell-Parameter wurden die signifikantesten Unterschie-
de zwischen den Tumor-Graden fu¨r die Transferraten K1 und k2 aus einem 1-Gewebe
Kompartiment-Modell mit Blutvolumen-Anteil (1TC-VB), k4 aus einem 2TC4k-VB Mo-
dell und fu¨r Parameter aus Patlak-Plots festgestellt. Es konnte gezeigt werden, dass
z.B. statische und kinetische Parameter-Bilder komplementa¨re Information liefern, und
somit eine Identifizierung von aggressiven Sub-Volumina und von Tumor-Heterogenita¨t
ermo¨glichen.
Die vorgestellten Ergebnisse sind vielversprechend, und bilden die Basis fu¨r zuku¨nftige
Anwendungen in der klinischen Routine, zur Verbesserung der Effizienz und Genauig-
keit diagnostischer Verfahren. Die na¨chsten Schritte sollten eine Validierung bei Ver-
dacht auf Tumor-Heterogenita¨t durch Entnehmen stereotaktischer Biopsien beinhalten.
Dies ko¨nnte eine Anwendung multi-parametrischer und multi-modaler Information fu¨r
eine Voxel-weise Klassifikation, oder eine Scha¨tzung von Wahrscheinlichkeits-Bildern
welche z.B. einen Krankheits-Progress oder ein Rezidiv auf Voxel-Basis vorhersagen,
ermo¨glichen.
Chapter 1
Introduction
Medical imaging has proven to be indispensable in clinical routine. This includes an
application for diagnostic purposes, treatment planning and monitoring, or the predic-
tion of disease progression. Besides morphological information, it is often desirable to
retrieve information on physiological or biochemical processes. This can be achieved
by the intravenous injection of a pharmaceutical, where a so-called carrier molecule
is selected to monitor a specific process of interest. For diagnostic purposes such a
pharmaceutical is often referred to as ”tracer” or ”contrast agent”.
In nuclear medicine the spatial and temporal distribution (biodistribution) of
a pharmaceutical within the body is ”traced” with a so-called radio-pharmaceutical,
where the carrier is labelled with a radionuclide. Images of gamma-emitting radioisotopes
can be acquired with a gamma (or scintillation) camera. 3-dimensional gamma camera
imaging is called single photon emission computed tomography (SPECT). To
be able to deduce the decay position within tissue, SPECT imaging relies on the appli-
cation of a collimator placed in front of the photon detection crystals, which confines
the solid angle of incident photons. Positron emitting radioisotopes have the advan-
tage that positron annihilation is followed by the emission of two photons, which are
emitted approximately in opposite directions (co-linear). This is utilised in positron
emission tomography (PET) to estimate the decay position from the respective line
of response (LOR), without requiring an absorbing collimator. Therefore, PET is
more sensitive and yields more uniform images with a higher resolution than SPECT for
clinical imaging.
Besides the usage for diagnostic purposes in oncology, cardiology, or neurology,
in-vivo targeting with radio-pharmaceuticals is also applied for targeted radionuclide
therapy including the assessment of delivered dose. Among others, a pharmaceutical
can for example mimic a metabolic substrate (e. g. glucose), specifically target recep-
tors (e. g. dopamine, benzodiazepine, serotonin, somatostatin, and others), amino acid
transporters, antigens, or translocator proteins (TSPO) [1–3]. Ideally such a radio-
pharmaceutical should be metabolically stable, provide a high specific binding, and
a low unspecific binding affinity. Also, the availability at the location of the molecular
target may become relevant, as it is the case e. g. for targets within the brain, where the
radio-pharmaceutical needs to cross the blood-brain-barrier (BBB, see section 2.4.4).
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Structure of this thesis
In this work first a summary on the essential methodological aspects for quantification
of brain PET images (chapter 2) is given. This includes basic principles of PET imag-
ing (section 2.1), quantification of physiological or biochemical properties (section 2.2),
and advanced image processing and analysis including voxel-based feature extraction
(section 2.3).
The study section (chapter 3) starts with preliminary phantom measurements, aiming
to establish and evaluate various threshold-based segmentation methods utilised for the
delineation of focal MS or glioma lesions. This is followed by two studies showing the
described methodological challenges arising for brain PET imaging, and aiming to enable
a clinical assessment of pathologies of the central nervous system.
Chapter 2
Background
2.1 Basic principles of positron emission tomography
In this chapter the basic principles of nuclear physics are summarised for imaging with
positron emission tomography. A detailed description on the respective aspects of nuclear
physics can be found in [4–6].
2.1.1 Radioactive decay
The spontaneous radioactive decay of an unstable nuclide can be described as an exother-
mic process where either mass is converted into binding energy (Ebin) in order to
maximise the binding energy per nucleon, or excess energy is released by gamma ray
emission. The so-called mass defect (∆m) describes the phenomenon, that the mass
of a nucleus composed of protons and neutrons is smaller than the mass of the sepa-
rate nucleons. Due to the short-range nuclear force the aggregation of nucleons can be
energetically favourable. The released binding energy corresponds to the mass defect
(equivalence of mass and energy):
Ebin = ∆m · c2 = [Z ·mp +N ·mn −m(Z,N)] · c2 , (2.1)
where c is the speed of light, Z the atomic or proton number, and N the neutron number.
The binding energy is described semi-empirically by the Bethe-Weizsa¨cker mass for-
mula. This means, that mathematical assumptions are derived from a simplified model
description of the nucleus (liquid drop model) and used to fit a model to experimentally
determined binding energies:
Ebin = av ·A− as ·A2/3 − aC · Z
2
A1/3
− aa · (A− 2Z)
2
A
+

+ap ·A−1 Z, N even
0 A odd
−ap ·A−1 Z, N odd
,
(2.2)
where the parameters ai with i ∈ {v, s, C, a, p} quantify the contribution of each term
to the binding energy, and A = Z +N is the nucleon or mass number.
• Volume (av): The short-range nuclear force is a secondary effect of the strong force
between quarks. For a better understanding, this can be compared to the hydrogen
bridge bond between neutral water molecules, which is a secondary effect of the
coulomb force. Due to the short range each nucleon they only interact with the
nearest neighbours.
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• Surface (as): The binding of nucleons at the surface is reduced due to a lower
number of neighbouring nucleons. This effect is comparable to the surface tension
effect of liquids.
• Coulomb (aC): The coulomb repulsion of protons reduces the binding energy.
Therefore, stable nuclides with a high mass number are constituted of a higher
fraction of neutrons than protons.
• Asymmetry (aa): The Pauli exclusion principle states that identical fermions can-
not occupy the same quantum state simultaneously. Thus, additional fermions
occupy higher energy levels (with a lower binding energy). Therefore, the same
number of protons and neutrons is energetically favourable, if coulomb interaction
is neglected.
• Pairing (ap): The last term takes into account spin coupling of particle pairs.
Hence, an even Z or N is preferred compared to an odd Z or N.
Unstable nuclides with too many neutrons are called n-unstable and tend to undergo
β− decay. Nuclides with too many protons (p-unstable) undergo β+ decay or electron
capture (EC). For a very high mass number α decay or spontaneous fission can occur
due to the increased influence of the coulomb term.
2.1.2 Statistical description of radioactive decay
Radioactive decay of statistically independent nuclides can be described as a Bernoulli
process (binomial probability distribution). Under the assumption that the number of
mother nuclides (N) is large compared to the number of decay events (dZ = −dN),
the total number of decays (Z) in a given time interval can be drawn from a Poisson
distribution
P (Z) =
Z¯Z
Z!
· e−Z¯ , (2.3)
where Z¯ is the average number of decays. For a large Z this can be approximated by
a symmetrical Gaussian distribution N (µ = Z¯, σ =
√
Z¯). However, both is only an
approximation of the underlying binomial distribution, and the applicability should be
validated for each purpose [7].
The average decay rate (in the following denoted without bars) is proportional to
the number of present mother nuclides:
dZ(t)
dt
= −dN(t)
dt
= λ ·N(t) , (2.4)
where the proportionality factor is the decay constant λ. This equation can be solved
with an exponential law
N(t) = N0 · e−λt , (2.5)
with radionuclide half-life T1/2, i. e. N(t = T1/2) = N0/2:
T1/2 =
ln(2)
λ
. (2.6)
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The activity A(t) is defined as:
A(t) =
dZ(t)
dt
= −dN(t)
dt
= λN(t) = λN0 · e−λt
= A0 · e−λt .
(2.7)
2.1.3 Positron emission tomography
β decay processes are isobar transitions, i. e. the mother and daughter nuclides have
the same mass number A. During β+ decay, which is utilised for PET imaging, a proton
is transformed into a neutron, a positron (e+), and – to preserve lepton number – an
electron neutrino (νe):
A
Z X→ AZ−1X˜ + e+ + νe . (2.8)
Due to the created positron and the higher neutron mass, the released binding energy
must equal at least twice the electron mass (me). As a consequence, p-unstable nuclides
with a transition energy lower than 2 × 511 keV = 1022 can only decay by electron
capture (EC). The remaining excess energy released during β+ decay is distributed
as kinetic energy among the decay products. This results in a continuous e+ energy
spectrum, which is characteristic for the decaying radionuclide. A short excerpt of
radionuclides applied for imaging with PET is given in table 2.1, showing the respective
mean energies and ranges. The most frequently applied radionuclide for PET imaging
is fluorine-18 (18F), which has a relatively long half-life, a short positron range, and can
be deployed as a hydrogen substitute.
Radio- Half-life Decay modes Ee+,mean Re+,max Re+,mean
nuclide (min) (%) (keV) (mm) (mm)
18F 109.7 β+(97), EC(3) 252 2.6 0.7
11C 20.4 β+(100) 390 4.5 1.3
13N 10.0 β+(100) 488 5.6 1.7
15O 2.0 β+(100) 730 9.1 3.0
68Ga 67.7 β+(89), EC(11) 844 10.3 3.6
82Rb 1.3 β+(95), EC(5) 1551 18.6 7.5
Table 2.1: Characteristics of exemplary positron emitting radionuclides used in PET
imaging: half-lifes, decay modes, mean energy (Ee+,mean), maximal (Re+,max) and mean
range (Re+,mean) of emitted positrons in water [8, 9].
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Figure 2.1: a: β+ decay followed by positron annihilation and an approximately co-linear
emission of two photons. b: Coincidence detection by a detector pair and estimated line
of response (LOR).
The positron slows down in tissue due to elastic scattering, ionisation, or excitation
processes. After the positron is slowed down in tissue, it either undergoes directly
free annihilation with a bound electron, or first combines with an electron and builds
a hydrogen like bound state called positronium. In most cases the positronium then
annihilates by co-linear two-photon (2× 511 keV) emission. The connection line between
two detection points is defined as the line of response (LOR) (figure 2.1). The
probability of positron annihilation increases for low energies. Positron annihilation
at rest results in a co-linear photon emission in opposite directions. Due to momentum
conservation residual kinetic energy can cause small angle deviations of about 0.2 degrees
[10].
When two detectors measure incident photons within a specified coincidence time
window and photopeak energy window, it is assumed that the two photons originate
from the same annihilation process. However, the detected coincidences can include
true, random, scattered, and multiple events. An encompassing summary on different
types of events and correction approaches is e. g. given by Leahy and Qi [11].
The activity concentration fk within voxel k = 1, ...,K is measured by coincidence
detection of detector pairs d = 1, ..., D. The measured projection data yd originating
from the LOR defined by detection pair d, can be mathematically described by the
application of a forward projection matrix, the so-called system matrix Hdk:
yd =
K∑
k=1
Hdk · fk + bd , (2.9)
where the scattered and random fractions are inserted as an additive error term bd =
bd,sc + bd,ra. The system matrix Hdk includes all relevant (image degrading) processes
affecting the measurement of true events: positron range, scanner geometry, attenuation
within tissue, detector blur, and sensitivity (matrix application order from right to left)
[11]:
H = Hsensitivity ·Hblur ·Hattenuation ·Hgeometry ·Hpositron . (2.10)
Further corrections which can be applied include e. g. decay and motion correction.
Attenuation correction is ideally performed based on measured transmission data.
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2.1.4 Tomographic image reconstruction
A straight forward analytical 2D image reconstruction can be performed by simply back-
projecting the measured yd with filtered back-projection (FBP). In order to enable
the restoration of sharp object boundaries, additional filters have to be applied on pro-
jection data before backprojection. Advantages of FBP reconstruction are the simplicity
and efficiency. However, it is not possible to incorporate a model of image degrading
factors or statistical noise.
Therefore, iterative image reconstruction has been implemented. This procedure
aims to find the most probable image estimate fˆ , i. e. maximising the probability to ob-
tain the measured projections yd. Assuming that the measured yd are Poisson distributed
(section 2.1.2), the likelihood function can be written as
L(f) = P (y|f) =
∏
d
e−y¯d · (y¯d)
yd
yd!
, (2.11)
with y¯d =
∑
kHdkfk + bd (from equation (2.9)). The maximum likelihood estimate can
be derived by maximising the monotonically increasing log-likelihood function l(f) =
lnL(f), i. e. by solving ∂ lnL(f)∂f = 0 with fixed point iteration. This yields the following
maximum likelihood expectation maximisation (MLEM) equation for iterative
reconstruction [11,12]:
fˆn+1k =
fˆnk∑
d′ Hkd′
·
[∑
d
Hkd ·
(
yd∑
kHdkfˆ
n
k + bd
)]
. (2.12)
This iteration equation provides positive image estimates in case of a non-negative initial
estimate f0d > 0. Moreover, iterative reconstruction provides better noise properties than
FBP (higher signal-to-noise ratio, SNR), especially for low activities. For an accelerated
convergence of the procedure ordered subsets EM (OSEM) was introduced, where
each iteration step is applied on a varying subset of the data [13].
2.1.5 System point spread function
In general the term partial volume effect (PVE) relates to image degradation due to
two different phenomena: (1) a finite image resolution depending on the point spread
function (PSF) of the imaging system resulting in a so-called spill-in and spill-out
of activity with respect to a target region, and (2) a simple sampling effect due to a finite
voxel size of the images, which becomes relevant when different tissue types are enclosed
within one voxel [14–16]. The width and shape of the system PSF depends on the image
degrading processes described in section 2.1.3. Attarwala et al. [17] found that the PSF
is best described by three 3-dimensional Gaussian functions, which further underlines
the influence from multiple processes.
For simplicity reasons it is assumed here, that the PSF is spatially invariant and
independent of the activity distribution f(r) (linear system). Hence, the measured
image g(r) can be described as a convolution of object f(r) with the PSF and an error
term n(r) (assumed to be additive):
g(r) = f(r)~ PSF(r) + n(r). (2.13)
A simple deconvolution can be performed using the Fourier transformation (FT) oper-
ation FT(f(r)) = F (u) =
∫
R f(r) · e−2piiurdr, with spatial frequency u. The PSF in
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frequency domain is called modulation transfer function (MTF). FT applied to
equation (2.13) gives
G(u) = F (u) ·MTF(u) +N(u) . (2.14)
By a simple rearrangement of equation (2.14), and a subsequent transformation back
into the spatial domain, the deconvolution can be expressed as
f(r) =
∫
R
G(u)−N(u)
MTF(u)
· e2piiudu . (2.15)
Unfortunately, for a decreasing MTF(u) at high spatial frequencies u the noise term
becomes dominant. Therefore, several other deconvolution methods have been devel-
oped [18, 19]. This includes methods directly applied during reconstruction, and meth-
ods applied post reconstruction. During iterative image reconstruction the system PSF
can be incorporated in the system matrix, which simultaneously can improve noise prop-
erties, but causes Gibbs artefacts at object boundaries (corresponding to high spatial
frequencies, where the system MTF is zero), and yields unreliable quantification for small
lesions [20]. Post reconstruction methods have to deal among others with the described
noise-amplification issue [21–23].
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2.2 Quantification of tracer pharmacokinetics
The gold standard for evaluation of physiological and biochemical processes from dy-
namic PET data is compartmental modelling. This relies (1) on invasive continuous
arterial blood sampling and a subsequent determination of free parent in plasma frac-
tion, and (2) on non-linear regression with multiple fitting parameters. Non-linear fitting
minimising an objective function (e. g. least squares) may provide several local minima
and not an explicit solution, and is not time-efficient in case of a voxel-wise estimation
of parametric maps [24,25].
For the determination of inter- and intra-patient comparable macro-parameters it is
in general desirable to provide a less extensive, but still reliable, and robust method. This
was for example achieved by graphical analysis (GA) aiming to linearise the model
equations in order to apply linear regression [26–29]. GA has the further advantage
that no a priori knowledge on the exact compartmental model is required (data-driven).
Yet, the main drawback remains the need for arterial blood sampling. As a consequence
several approaches have been proposed using image-derived information [30–32].
The first section of this chapter summarises the basic principles of compartmental
modelling and discusses the determination of an arterial input function. This is followed
by an introduction to graphical analysis and reference tissue modelling. The last section
of this chapter deals with quantification based on heuristic parameters.
2.2.1 Compartmental modelling of specific and non-specific binding
Compartmental models are introduced in order to provide a suitable description of phy-
siological and biochemical processes by quantifying the spatial and temporal distribution
of a radio-pharmaceutical within the body, i. e. the time-dependent delivery, retention,
and clearance of tracer after intravenous injection [33]. In such models the spatial (e. g.
different organs, tissues, or vessels) and biochemical state (e. g. parent, metabolised,
specifically bound, or trapped compound) of the tracer is represented by separated com-
partments i, and the temporal change of the respective tracer concentration Ci(t) is
quantified by transfer rates (first-order rate constants) for tracer influx kij from, and
eﬄux kji to compartment j:
d
dt
Ci(t) =
N∑
j 6=i;j=1
[kij · Cj(t)− kji · Ci(t)] , (2.16)
where N is the number of compartments considered in the pharmacokinetic model [34].
The applicability of such models relies on the following assumptions [35]: (1) the injected
amount of tracer is low enough to have no influence on the physiologic and molecular
processes of interest, which (2) are assumed to be constant during the scan time; (3)
tracer concentration is homogeneously distributed (instantaneous mixing) within the
distinct compartments.
Since tracer is injected intravenously, it is important to include an plasma input
function (IF) compartment, representing the tracer delivery to a tissue of interest from
arterial plasma CP (t). Integration of equation (2.16) and subsequent summation over all
compartments i yields a model representation for the total tissue concentration CT (t),
which can be expressed for linear compartmental systems in terms of a convolution of
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the plasma input function with an impulse response function (IRF) [36]:
CT (t) = CP (t)~ IRF(t)
=
∫ t
0
CP (τ) · IRF(t− τ)dτ
IRF(t) =
N−1∑
i=1
φi · e−θit ,
(2.17)
where φi and θi are functions of the transfer rate constants, and N − 1 is the number of
tissue compartments (excluding the arterial plasma compartment). In general, not only
different tissue compartments, but blood vessels themselves can be present within the
assessed tissue volume. The fractional blood volume VB, and the whole blood concen-
tration CB can be included in equation (2.16) [36]:
CT (t) = VB · CB(t) + (1− VB) · CP (t)~ IRF(t) . (2.18)
For models with only few compartments, the transfer rates in equation (2.16) are
indexed with numbers, e. g. K1 is the transfer rate from blood to tissue (clearance,
K1 =
∑N−1
i=1 φi [36]), and k2 the transfer rate from tissue to blood. If the eﬄux transfer
rate is negligible for at least one compartment, the model is called irreversible. This
assumption can also be applied for PET radio-pharmaceuticals with very slow reversible
binding kinetics, i. e. showing an continuously increasing kinetic without washout within
the scanning time-window [37].
Model selection
In case of new radio-pharmaceuticals, the capability of different models to appropriately
describe the measured data needs to be assessed. A summary on common compartmental
model selection criteria which quantify the goodness of fit can be found in [38,39]. The
optimisation algorithm itself, the chosen weighting method, parameter constraints, and
in case of voxel-wise fitting the noise reduction strategies are of high importance [40,41].
For example, compartmental models are frequently compared using the corrected
Akaike information criterion (AICC), which is suitable in case of a high number of
parameters p compared to the sample size n (n/p ≤ 40) [39,42]:
AICC = n · ln (WRSS) + 2 · p+ 2 · p · (p+ 1)
n− p− 1 , (2.19)
where WRSS is the weighted residual sum of squares defined as the sum over
the squared errors, i. e. the differences between measured activity concentrations Cf in
frames f and the fitted values C˜f :
WRSS =
∑
f
wf · (Cf − C˜f )2. (2.20)
General compartmental model considerations
In a simplified tracer model (figure 2.2, VB neglected), total tissue concentration CT (t)
can be interpreted as a combination of specifically (S) and non-specifically (NS) bound
tracer, and of tracer freely (F) available in tissue:
CT (t) = CS(t) + CNS(t) + CF (t). (2.21)
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Non-displaceable (ND) tracer concentration is defined as: CND(t) = CNS(t) +CF (t)
[43,44].
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Figure 2.2: Schematic illustration of a 3-tissue compartment (3TC) model incorporating
concentrations of plasma input CP (t), free tracer in tissue CF (t), non-specific CNS(t)
and specific binding CS(t). CF (t) and CNS(t) can be merged to one non-displaceable
compartment with CND(t), yielding a 2TC model. In a 1TC model no tissue compart-
ments are differentiated.
Perfusion and extraction fraction
Several physiological parameters are relevant for the exchange of tracer between blood
plasma and brain tissue across the blood-brain barrier. While blood flow is defined
as the blood volume delivered per unit of time (units mL · min−1), perfusion (F )
is defined as the volume of blood delivered per unit of tissue mass and time (units
mL·g−1 ·min−1) [5,44]. The product of permeability (P ) (units cm·min−1) and available
surface area (S) per unit of tissue volume (units cm2 · g−1) is called the permeability
surface area product (PS, units mL · g−1 · min−1). From the PS the (unitless)
extraction fraction E can be derived, which quantifies the fraction of tracer transferred
from blood to tissue during first pass through the capillary (unidirectional). In the
Renkin-Crone model a capillary is assumed to be a rigid cylindrical tube [45,46], yielding
E = 1− e−PSF , (2.22)
i. e. E increases with PS and decreases with F . With this the transfer rate from blood
to tissue can be expressed as the product of perfusion and extraction fraction:
K1 = F · E , (2.23)
which increases with perfusion F for higher PS values [35].
Equilibrium condition and quantification with macro-parameters
Since relative tracer concentrations vary over time, a robust quantification can only
be achieved under the condition of a true equilibrium. This is reached, when the
steady state condition for blood (dCP (t)dt ≈ 0) and tissue (dCT (t)dt ≈ 0) is fulfilled over a
period of time, similar to le Chatelier’s principle for chemical reactions. This should not
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be confused with the peak of tissue tracer concentration after bolus injection. Under
the idealised assumption of a closed system, true equilibrium can be approximated by
constant tracer infusion [47, 48]. Tissue uptake CT of reversible tracers at equilibrium
relative to plasma concentration CP is quantified by introducing the concept of volume
of distribution (VT ):
VT =
CT
CP
. (2.24)
Specific uptake CS = CT − CND at equilibrium relative to a chosen reference con-
centration CX is defined as binding potential (BP): BPX =
CS
CX
= CT−CNDCX . For
example specific uptake relative to plasma concentration CP yields BPP =
CT−CND
CP
=
VT − VND = VS and relative to non-displaceable uptake CND [44] yields
BPND =
CT − CND
CND
. (2.25)
VT and BPND can either be obtained by performing a continuous infusion protocol, or
in case of a single bolus injection by performing kinetic modelling. For a compartmental
model defined according to equation (2.17), VT can be calculated as [24,36]:
VT =
∫ ∞
0
IRF(t)dt =
N−1∑
i=1
φi
θi
. (2.26)
In case of irreversibly binding tracers equilibrium condition cannot be reached for the
entire tissue, and the above mentioned macro-parameters VT , and BPND are not appli-
cable. Irreversible tracer kinetics are described instead by a net influx rate Ki from
plasma into the irreversible compartment n (θn = 0 in equation (2.17)) [36]:
Ki = lim
t→∞ IRF(t) = φn . (2.27)
For bolus injection of reversibly binding radio-pharmaceuticals only a pseudo- (or
relative) equilibrium can be reached, which is defined as a state during which the
ratio of tissue and plasma concentration is constant over time: CT (t)CP (t) ≈ const. This
constant ratio is referred to as apparent volume of distribution, and does not correspond
to VT at true equilibrium [35].
One- and two-tissue compartment models
PET tracers intended to measure perfusion (no specific binding) can be modelled by an
1-tissue compartment (1TC) model. Setting N = 2 in equations (2.16) and (2.17)
yields:
d
dt
CT (t) = K1 · CP (t)− k2 · CT (t) ,
CT (t) = CP (t)~K1e−k2t ,
and VT =
K1
k2
.
(2.28)
The equation of a 2TC model (N = 3 in equation (2.17)) is:
CT (t) = CP (t)~
[
φ1 · e−θ1t + φ2 · e−θ2t
]
, (2.29)
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with φ1,2 and θ1,2 as specified in [37] this yields the macro-parameters of reversible
binding
VT = VND · (1 + BPND) ,
with VND =
K1
k2
and BPND =
k3
k4
,
(2.30)
and of irreversible binding (k4 = 0)
Ki = φ2 =
K1 · k3
k2 + k3
. (2.31)
Input function determination
The input function CP (t) for compartmental modelling should represent free unmetabo-
lised tracer concentration in blood plasma. Hence, not only a continuous measurement
of arterial blood activity concentration CB(t) is required, but also the determination
of free parent fraction in plasma for several discrete time points. Separation of plasma
from blood cells is generally performed by centrifugation, yielding a plasma-to-blood
ratio (fpwb). For extraction of plasma parent fraction (fppf), the most common
procedure is to perform high-pressure liquid chromatography (HPLC) on plasma sam-
ples, followed by fitting a mathematical function to the discrete data [49]. Lastly, the
plasma free fraction (fp) can be determined, in order to exclude the fraction of tracer
non-specifically bound to plasma proteins. Typically, it is assumed that fp is constant
during the scan time. However, fp measurements (e. g. with ultrafiltration) have a high
level of uncertainty [50]. Therefore, fp is often neglected. Nevertheless, knowledge on
fp can support the understanding of new tracer properties. Moreover, the measurement
of CB(t) with a continuous blood sampler [51,52] itself can be prone to errors, orig-
inating from noise in measured data and tubing effects (e. g. clotting, sticking to tube
walls for lipophilic tracers) [53,54].
Despite the susceptibility to methodological errors, high cost, and patient discom-
fort, the gold standard for quantification of physiologic processes remains the extraction
of CP (t) from blood samples. For parent fraction estimation of metabolically unsta-
ble tracers, it is inevitable to draw a few blood samples. Nevertheless, it is desirable
to replace the invasive and time-consuming continuous blood sampling by other meth-
ods. For example CB(t) can be directly estimated from PET images [31, 32, 53, 55–57],
measured e. g. with non-invasive wrist detectors [58–60], or derived based on a rescaled
population-based standard IF [61,62]. The reliability and applicability of an image-
derived input function (IDIF) has shown to be tracer specific, and dependent on
image quality (correction for partial volume effects), i. e. the ability to recover signal
over a large range of activity concentrations within arteries or blood pools of varying
size [53,57,63].
2.2.2 Graphical analysis
Compartmental modelling relies on non-linear fitting and prior knowledge on the model
structure. The high computational cost and sensitivity to initial estimates becomes
especially important in case of fitting noisy time-activity curves (TACs) of single voxels
[25]. In most cases the macro-parameters described in section 2.2.1 are of interest, which
are independent of a specific compartmental configuration. Hence, so-called graphical
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analysis (GA) methods aim to estimate the macro-parameters using simplified linear
regression analysis [64,65].
The linear relation is basically obtained by assuming a pseudo-equilibrium condition
(see section 2.2.1) for times t > t∗ for all reversible compartments, and by rearranging
the model equation (2.16). For irreversibly binding tracers Patlak et al. [26,66] proposed
the following linear equation for estimation of the net uptake rate Ki with Patlak plot:
CT (t)
CP (t)
= Ki ·
∫ t
0 CP (τ)dτ
CP (t)
+ Int . (2.32)
Logan et al. [28] introduced a method to estimate distribution volumes for reversible
tracers with Logan plot:∫ t
0 CT (τ)dτ
CT (t)
= VT ·
∫ t
0 CP (τ)dτ
CT (t)
+ Int . (2.33)
The Logan plot has the disadvantage that VT estimates are sensitive to noise in CT (t)
data, especially for high specific binding regions in which the pseudo-equilibrium con-
dition can be violated. This results in an underestimation of VT in regions with high
specific binding [67, 68]. This issue was approached by several groups [29, 69, 70]. For
example Zhou et al. [68, 70] validated the performance of a new linear equation termed
relative equilibrium-based (RE) plot,∫ t
0 CT (τ)dτ
CP (t)
= VT ·
∫ t
0 CP (τ)dτ
CP (t)
+ Int , (2.34)
and a combined application of RE plot and Patlak plot called RE-GP plot [68].
2.2.3 Reference tissue modelling
The GA methods described in section 2.2.2 still rely on the availability of an arterial
plasma input function. In addition to alternative methods for the extraction of an IDIF
(section 2.2.1), image-derived reference tissue TACs may be applied as an input function
and surrogate for non-displaceable tracer uptake. The main requirements which an ideal
reference tissue (RT) should fulfil are: (1) RT should be devoid of specific uptake (i. e.
BP’ND = 0), (2) V
′
ND in the RT should be similar to VND in the tissue of interest, and
(3) uptake in the RT should not be influenced by the disease or treatment [71, 72]. By
directly applying assumptions (1) and (2), tissue BPND can be estimated for reversibly
binding tracers (equation (2.25)) [73] with:
BPapparent =
VT
V ′T
− 1
=
VND · (1 + BPND)
V ′ND · (1 + BP′ND)
− 1
(1),(2)≈ BPND .
(2.35)
The ratio VT
V ′T
is referred to as distribution volume ratio (DVR). A comprehensive
summary and comparison of several reference tissue methods including full reference
tissue model, simplified, and multilinear approaches can be found in [74]. A discussion
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on the influence of assumption violations for the simplified reference tissue model is
provided by [75].
Macro-parameter estimation based on a reference tissue input function can be com-
bined with graphical analysis as introduced in the previous section. The respective GA
reference tissue model equations are [28,65,69,76]:
Patlak:
CT (t)
C ′T (t)
=
Ki
V ′T
·
∫ t
0 C
′
T (τ)dτ
C ′T (t)
+ Int ,
Logan:
∫ t
0 CT (τ)dτ
CT (t)
= DVR ·
∫ t
0 C
′
T (τ)dτ + C
′
T (t)/k¯
′
2
CT (t)
+ Int ,
RE (Zhou):
∫ t
0 CT (τ)dτ
C ′T (t)
= DVR ·
∫ t
0 C
′
T (τ)dτ
C ′T (t)
+ Int ,
(2.36)
where k′2 in the Logan reference tissue model is approximated by the population average
k¯′2, and is negligible in many cases [76].
2.2.4 Quantification based on heuristic parameters
Despite the huge amount of possible quantification methods estimating the macro-
parameters described in section 2.2.1, extensive modelling is rarely applied in clinical
routine. Due to obvious reasons such as patient comfort, clinical throughput and work-
load, it is desirable to assess disease status based on heuristic parameters derived from
static images.
As delineated in section 2.2.1, concentration ratios derived under pseudo-equilibrium
condition are quantitatively different from true VT . Nevertheless, a (semi-) quantitative
assessment with simple ratios (target tissue relative to an appropriate reference tissue)
has shown relevance for various clinical applications. The goal of heuristic quantifi-
cation is to provide sufficient and reliable information for disease assessment, with a
high inter- and intra-patient comparability, without requiring an exact quantification of
physiological and biochemical processes.
When no appropriate reference tissue is available, a normalisation of image values
can also be based on known influences from confounding factors like injected activity
and patient weight [77, 78]. The utilisation of (unitless) standardised uptake values
(SUV) is still a widely used quantification procedure in clinical routine:
SUV =
activity concentration [kBq/mL]
injected activity [MBq] / patient weight [kg]
. (2.37)
For some clinical applications a heuristic description of time-activity curve (TAC)
kinetics derived from dynamic PET data has been established [79]. This includes for
example the time-to-peak (TTP), peak SUV (SUVpeak), area under the curve (AUC),
and early or late TAC-slopes (figure 2.3). Furthermore, a normalisation of uptake values
from static images to an appropriate reference tissue can be performed, yielding so-called
SUV ratios (SUVR) or target-to-background ratios (TBR).
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Figure 2.3: Illustration of some established heuristic parameters utilised for the charac-
terisation of TAC kinetics.
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2.3 Image processing and analysis
The goal of image processing is to enable and improve the correlation of PET informa-
tion with disease classification, progression, and other clinically relevant parameters, or
the identification of significant differences between groups. The most common methods
for statistical analysis in functional brain imaging rely on the definition of a volume
of interest (VOI), from which average parameters can be derived. Segmentation of
structures in medical images in general is of high interest resulting in a large number
of publications trying to optimise methodology. In functional brain PET imaging ei-
ther pronounced lesions with an elevated uptake can be segmented [80, 81], or certain
brain regions of interest can be delineated based on additional information from e. g.
morphological T1-weighted magnetic resonance imaging (MRI) in combination with a
pre-defined probabilistic brain atlas [82].
However, when imaging diffuse uptake variations in the brain without prior know-
ledge on the dissemination of disease, it can be helpful to perform statistical analysis
on a voxel basis. This can be applied for the assessment of different kinds of cen-
tral nervous system disorders, including e. g. epilepsy, infection, spinal cord injury, or
neurodegenerative diseases such as Alzheimer’s disease or multiple sclerosis.
In the following, several image processing methods, aiming to improve information
content extracted from functional brain PET images, are presented. This includes meth-
ods optimising segmentation in functional brain images, probability atlas-based struc-
tural segmentation methods, voxel-wise analysis based on statistical parametric maps
(SPM), and a brief summary on methods for the characterisation of objects and inten-
sity distributions with histogram analysis, texture analysis, and shape parameters.
2.3.1 Image segmentation methods
VOI-based quantification of lesions does not only depend on the quality of PET images
(e. g. PVE), but also on the performance and reliability of the chosen segmentation al-
gorithm. Besides volume-based quantification for diagnostic purposes, the estimation of
3-dimensional lesion extent is also essential for the definition of target volumes in radia-
tion therapy. Hence, segmentation either aims to estimate true lesion volume (boundary
reproducing), or to deliver real intensity estimates. In case of ideal images without noise,
a delta-shaped space-invariant system PSF, and high resolution, a boundary reproducing
volume segmentation would simultaneously deliver correct intensity values. However, the
image degrading factors introduced in section 2.1.3 cannot be neglected. One approach
to solve both tasks at once, is to either apply segmentation on images corrected for PVE,
or to utilise boundary reproducing segments for a posteriori correction of PVE. For im-
ages reconstructed with PSF-based iterative algorithms, a threshold-based segmentation
of volumes can be challenging due to uncontrolled amplification effects at object bound-
aries. This work will focus on the segmentation of realistic volumes, bearing in mind a
possible application of techniques compensating the PVE.
Due to a high inter- and intra-operator variability, and dependency on the viewing
conditions of colour bars etc., a manual segmentation in case of activity images is not
advisable. Automatic segmentation of lesions in static activity concentration images
can either be based on fixed or iterative [83–86] thresholds, or on variational tech-
niques (e. g. level-sets, active contours, gradient-based watershed segmentation) [80,81].
Strictly speaking, a purely threshold-based approach for segmentation in static PET
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images is only valid under the following assumptions: (1) spherically shaped object, (2)
homogeneous intensity distribution within the object, (3) isotropic and spatially con-
stant system PSF. Consequently, for more complex shaped objects the application of
variational methods might be favourable. Additionally, several advanced segmentation
methods which are applicable to multi-parametric image datasets have been developed
and partly applied on PET data, including data driven clustering [87] or supervised
classification [88, 89] methods algorithms.
2.3.2 Atlas-based segmentation with maximum probability maps
For a voxel-wise comparison of brain PET images, and for the application of anatomical
atlas VOIs on functional PET data, a spatial transformation into a standard template
space is useful. The two most common stereotactic template spaces for brain mapping
are Talairach and MNI (Montreal Neurological Institute) space. For atlas-based segmen-
tation the two following steps need to be performed: (1) deformable registration of the
patient image to an image of the same modality in template space [90] and (2) segmen-
tation based on atlas information. A summary on template spaces and brain atlases can
be found in [82].
Due to a high inter-subject variability of anatomical brain structure, the concept of
a population-based probabilistic atlas was developed, where a 3D brain structure
is not represented by a single average atlas, but preserves information on inter-subject
variability. Such a probabilistic map can be generated from a population of subjects,
which are first mapped into a chosen stereotactic space and intensity normalised, then
manually assigned to a tissue class. Finally, a probability map for each tissue class can
be derived [91]. This probability maps can either be directly utilised by segmentation
algorithms, or a so-called maximum probability atlas can be derived, where each
voxel in template space is assigned to the most frequent label. Within the PMOD Neuro
tool (PMOD Technologies, Zurich Switzerland), which was utilised in this work, the
N30R83 maximum probability atlas for segmentation of T1-weighted MRI images in
MNI space is implemented and provides 83 brain structures [92,93].
2.3.3 Statistical parametric mapping
For the 3-dimensional characterisation of activation or deactivation in functional images
in neurology, Friston et al. [94,95] introduced the concept of statistical parametric maps
(SPMs), i. e. colour-coded distributions of statistical significance. The tests provided
within the dedicated SPM software developed by the Wellcome Centre for Human Neu-
roimaging (University College London, UK) include for example analysis of variance
(ANOVA), correlation, or regression analysis. With the provided methodology images
containing a disease related elevated or degraded uptake can be compared on a voxel
basis to a set of healthy control images or to other patient images. Alternatively, e. g. a
voxel-wise correlation with clinical parameters can be performed. Moreover, the possibil-
ity to incorporate confounding nuisance variables (frequently e. g. age and gender)
is provided. Statistical tests assuming non-parametric variables are not incorporated in
the SPM software, but have been addressed e. g. by Holmes et al. [96].
The frequently applied ANOVA either focuses on differences between subjects (only
one image per subject, simple ANOVA), or on differences between repeated measures
of the same subjects. This can include multiple experimental factors (different types
of parameters, conditions) for each observed level. A level represents e. g. a patient or
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healthy controls group, or different time points for repeated measures. For example a
simple one-way (one factor) ANOVA with 2 levels is equivalent to the two-sample t-test,
and a one-way within-subject ANOVA is equivalent to a paired t-test.
In the following section first the statistical methods relevant for SPM analysis are
described at a single voxel level. Next a short introduction to cluster level inferences
is given, incorporating spatial connectedness and the assumption of an expected cluster
size.
Multivariate linear regression model
The multivariate linear regression model (MLRM) (also called general linear
model) forms the basis of statistical analysis in SPM. Let j = 1, ..., J be the scan number,
and l = 1, ..., L the number of covariates, confounding effects, or levels of ANOVA,
then the response variable Yj (dependent, regressand, or explained variable) can be
expressed as a linear combination of explanatory variables xjl (also called regressors,
covariates, or independent variables forming a design matrix X), and an additive error
term (disturbance, or noise) consisting of independent identically distributed random
variables j
iid∝ N (0, σ2) (Gaussian with zero mean and variance σ2):
Yj =
L∑
l=1
xjl · βl + j . (2.38)
For example the MLRM of linear regression can be formulated as Yj = µ + xj · β + j ,
where β is the regression slope and µ is a constant term.
Equation (2.38) has no explicit solution, due to the unknown error terms. Conse-
quently, the parameters βl need to be estimated, aiming to provide an optimal fit to
the measured data. This can be achieved e. g. by minimising the sum of squared errors,
i. e. the difference between experimentally determined observables Yj and fitted values
Y˜j =
∑L
l=1 xjl · β˜l:
S =
J∑
j=1
(Yj −
L∑
l=1
xjl · β˜l)2 . (2.39)
By solving ∂S
∂β˜l
= 0, and assuming that (XTX) is invertible, the following ordinary least
squares estimates βˆ can be obtained:
βˆl =
 J∑
j=1
xlj · xjl
−1 J∑
j=1
xlj · Yj
or βˆ = (XT ·X)−1 ·XT · Y .
(2.40)
For the normally distributed parameter estimates βˆ ∝ N (β, σ2 · (XT · X)−1) applies.
Multiplication with a contrast vector c (
∑L
l=1 cl = 0) yields c
T · βˆ ∝ N (cT · β, σ2 · cT ·
(XT · X)−1 · c). Consequently, the test statistic T (t-score, Student’s t-distribution)
can be expressed as
T =
cT · βˆ − cT · β√
σˆ2 · cT · (XT ·X)−1 · c , (2.41)
where the difference between estimated and measured data is normalised by the standard
deviation σˆ, resulting in a reduction of t-scores for high standard deviations.
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Two-sample t-test
As an example, here the MLRM terminology is applied on a simple two-sample t-test
between two independent groups (Y1j and Y2j), where the individual group effects are
represented by the mean values µ1 and µ2. This can be expressed as a MLRM:
Yq,j = xq,j1 · µ1 + xq,j2 · µ2 + 1,j , (2.42)
with xq,jl =
{
1 if q = 1
0 if q = 2
, x2,j2 =
{
0 if q = 1
1 if q = 2
, and β = [µ1, µ2]
T . This yields (XT ·
X) =
(
n1 0
0 n2
)
and (XT · X)−1 =
(
1/n1 0
0 1/n2
)
with the number of measurements
nq in group q. The null hypothesis states that both groups have equal mean values
H0 : µ1 = µ2, which can be rewritten by means of a contrast vector c = [1,−1]T as
cT · β = 0. Thus, we receive the formulation of the test statistic (equation (2.41)) of the
two-sample t-test:
T =
µˆ1 − µˆ2√
σˆ2 · (1/n1 + 1/n2)
. (2.43)
Global normalisation
One major issue addressed by SPMs is the extraction of significant local changes in-
dependent of the global activity level. The global activity can be biased either due to
instrumentation variability (such as injected activity or general scanner properties), or
due to a subject specific biological and physiological body composition (e. g. patient
weight).
The reduction of variability caused by a multiplicative effect can be achieved by
normalisation (proportional scaling) of the image data. The global activity level is
often estimated by the mean signal gj within the entire brain (global mean),
gj =
K∑
k=1
Y kj /K , (2.44)
where k = 1, ...,K enumerates the cerebral voxels, and Y kj is the intensity of voxel
k in scan j. This is only adequate, if effect-related activity changes are negligible.
Alternatively an appropriately chosen reference tissue fulfilling the criteria described in
section 2.2.3 can be utilised, including the requirement that gj needs to be independent
of the process of interest. The adapted MLRM is:
Y kj = gj
L∑
l=1
xjl · βkl + ′kj . (2.45)
Alternatively, as proposed by Friston et al. [97], analysis of covariance (AN-
COVA) can be utilised. Where a mean corrected global activity (gj− g¯) is incorporated
as an additional regression term (additive effect) within the MLRM:
Y kj =
L∑
l=1
xjl · βkl + ξk · (gj − g¯) + kj . (2.46)
Depending on the observed physiological process, the sensitivity of each voxel k to a
global change can vary across the brain. This is incorporated in the MLRM by the
subject-independent parameter ξk.
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Classical inference
After calculating the test statistic of each voxel, a decision rule needs to be specified, i. e.
a probability level below which the null hypothesis (H0) can be discarded. The threshold
is defined based on the null distribution of the test statistic, i. e. the probability distri-
bution in case of a true null hypothesis. A threshold u then leads to a false positive
rate (FPR) of α = p(t > u|H0). In the case of e. g. K = 100 000 voxels, an α-level of
0.05 leads to a large number (5 000) of false positive voxels (multi comparisons problem).
A simple Bonferroni correction for a family-wise error (αcorr =
αFWE
K ) is very conserva-
tive in case of spatially correlated voxels. Spatial correlation can be parametrised by
topological features in the test statistic image, such as peak height u (voxel level),
spatial extent k (cluster level), and the number of clusters c (set level) [98, 99]. In or-
der to incorporate topological constraints, a continuous description of the discrete test
statistic image can be implemented by applying (Gaussian) random field theory based
on expected Euler characteristics and image smoothness. While the regional sensitivity
is the highest for uncorrected data (i. e. application of height threshold t > uα), the
specificity (reduction of FPR) is enhanced when additionally restricting the cluster level
extent (> kα) or the number of clusters (cα).
2.3.4 Basic principles of object recognition and characterisation of
parametric 3D distributions
A simple VOI-based and a direct voxel-based quantification as described in the previous
sections can be complemented by the extraction of quantitative parameters characteris-
ing intensity histograms, intensity (grey level) changes within a VOI (texture), and
VOI shape. In the recent years such properties have gained growing popularity espe-
cially in the field of radiomics, which aims to reduce the need for invasive biopsies by
a non-invasive characterisation of tumour heterogeneity [100–102].
Histogram and texture parameters rely on a prior discretisation of intensity values
(binning), and depend on an overall intensity scaling. Discretisation of intensities within
a defined VOI can either be performed for a fixed number of bins per VOI or a fixed
bin width [103]. While a fixed bin width maintains the interpretation of intensities as
physiologic properties (e. g. functional images such as PET), a fixed bin number per VOI
focusses on normalised grey level changes within the VOI. Therefore, a fixed number of
bins might be preferred in case of arbitrary intensity units (e. g. morphological MRI
images). In contrast, a fixed bin size was found to be superior for e. g. PET derived
data [104,105].
Intensity- and histogram-based parameters
Common VOI statistics directly derived from intensities Ik of each voxel (k = 1, ...K) en-
closed within the VOI include e. g. mean value, standard deviation, minimal and maximal
intensity, parameter range, and coefficient of variation (COV). Less frequently applied
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parameters characterising the intensity distribution include e. g.:
Skewness =
1
N ·
∑N
k=1(Ik − µ)3(
1
N ·
∑N
k=1(Ik − µ)2
)3/2 and
Kurtosis =
1
N ·
∑N
k=1(Ik − µ)4(
1
N ·
∑N
k=1(Ik − µ)2
)2 − 3 .
(2.47)
The skewness is an asymmetry measure, which can be negative or positive, and the
kurtosis quantifies whether the majority of values is concentrated (peaked) around the
mean or distributed towards the tails of the intensity distribution. In equation (2.47)
the correction -3 is inserted in order to yield 0 for a normal distribution.
a b c
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Figure 2.4: Visualisation of a percentage volume fractions, and b, c cumulative percent-
age volume histograms for three exemplary intensity distributions. b Three different Iy
values for a fixed volume fraction PVH = y%, and c different PVHx values for a fixed
threshold I = x are shown.
The quantification of intensities within a VOI not taking into account the spatial
distribution of values can also be quantified with histogram data. The first order his-
togram can be normalised to the total number of voxels included in the VOI, yielding
the percentage fraction of voxels within the VOI (bin content) with a certain intensity
value (bin). This will be termed percentage volume fraction (PVF) in this thesis
(figure 2.4a). For a robust quantification either a large histogram bin size can be chosen,
or integration can be performed yielding a cumulated histogram (cumulative percent-
age volume histogram, PVH, figure 2.4b, c), where the volume fraction consisting
of voxels with an intensity above (or below) a certain threshold is plotted against the
threshold.
Quantification with cumulative histogram data can either focus on the intensity
threshold (Iy, figure 2.4b) obtained for a fixed PVH value (y%), or focus on a varying
volume fraction (PVHx, figure 2.4c) for a defined intensity threshold (x). The first is
often referred to as percentile. For example I10 and I90 can be applied instead of minimal
and maximal intensity, aiming to provide quantitative values which are more robust to
outliers. Based on such percentiles e. g. interquartile ranges are defined (Riq = I75−I25).
For parametric images quantifying a physiologic process, the intensity values beyond a
defined threshold (x) are assumed to be directly connected to a tissue property or disease
status. In this case, it might be beneficial to quantify the volume fraction (PVHx)
consisting of voxels with the characteristic property. Further PVF-based histogram
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parameters include e. g.:
Entropy = −
Nbins∑
b=1
PVF(b) · log2PVF(b) and
Uniformity =
Nbins∑
b=1
PVF(b)2 .
(2.48)
Quantification of texture by grey level changes
While a 1D intensity histogram gives the amount of voxels (bin content) with the same
intensity (bin), the amount of neighbouring voxel-pairs – where one voxel has intensity
i and the other intensity j – can be stored in a 2D histogram with matrix elements
Gij . The elements of the normalised grey level co-occurrence matrix (GLCM) are
defined as [106]
gij =
Gij∑
Gij
. (2.49)
According to this definition, the GLCM is symmetric. The following exemplary texture
parameters can be extracted:
EnergyGLCM =
∑
i,j
g2ij ,
EntropyGLCM = −
∑
i,j
gij · log2gij ,
CorrelationGLCM =
∑
i,j
(i− µ) · (j − µ) · gij
σ2
,
Inverse difference moment (Homogeneity)GLCM =
∑
i,j
gij
1 + (i− j)2 ,
Inertia (Contrast)GLCM =
∑
i,j
(i− j)2 · gij ,
Cluster shadeGLCM =
∑
i,j
((i− µ) + (j − µ))3 · gij ,
Cluster prominenceGLCM =
∑
i,j
((i− µ) + (j − µ))4 · gij , and
Haralick’s correlationGLCM =
∑
i,j i · j · gij − µi · µj
σi · σj ,
(2.50)
with the weighted pixel average µ =
∑
i,j i · gij =
∑
i,j j · gij , the weighted pixel variance
σ2 =
∑
i,j(i−µ)2 · gij =
∑
i,j(j−µ)2 · gij , and the means (µi/j) and standard deviations
(σi/j) of gi =
∑
j gij and gj =
∑
i gij [103,106].
Shape parameters describing morphology
The quantification of VOI shape and morphology in three dimensions relies on several
basic parameters, such as volume V , surface area A, maximum diameter, or smallest
(λleast), second largest (λminor), and largest (λmajor) principal component. The maxi-
mum diameter and principal components can be directly derived from voxel coordinates.
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The volume can either be calculated as a sum of voxel volumes included in the VOI,
or estimated from a triangle mesh representation of the VOI derived with a marching
cubes algorithm [107]. This method approximates the surface of an object within a cubic
voxel by a triangular mesh. The sum of tetrahedral volumes spanned by the triangles
i = 1, ..., Nf (with vertices ai, bi, and ci) and an arbitrarily defined image origin (O)
yields the total object volume
Vmesh =
Nf∑
i=1
Oai · (Obi ×Oci)/6, (2.51)
where the sign is different for outward and inward facing tetrahedrons. The surface area
can be approximated from the mesh with
Amesh =
Nf∑
i=1
|ai · bi × ai · ci|/2. (2.52)
From those basic parameters the following exemplary shape parameters can be derived
(assuming 3D images):
Surface to volume ratio = A/V ,
Sphericity or roundness =
3
√
36 · pi · V 2
A
,
Compactness =
V√
pi ·A3 ,
Elongation =
√
λminor
λmajor
, and
Flatness =
√
λleast
λmajor
.
(2.53)
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2.4 Imaging of brain pathology
For imaging of central nervous system (CNS) diseases, a deeper understanding on
the structure and function of the blood-brain barrier (BBB) is required. Firstly,
the prerequisite of functional brain imaging is a sufficient tracer availability, i. e. the
ability to cross the BBB. Secondly, BBB disruption plays a major role in the pathophy-
siology of CNS diseases, where BBB breakdown can occur as a primary process, or as
an secondary side effect of the disease [108]. This chapter gives a brief overview on BBB
function, pathophysiologic BBB changes, and on optimal properties for BBB penetration
of radio-pharmaceuticals.
2.4.1 The blood-brain barrier
Neuron
Astrocyte
Microglial cell
Pericyte
Tight junction
Endothelial
cell
Basement
membrane
Capillary
lumen
Figure 2.5: A schematic illustration of the structure of brain capillaries and the inter-
acting components of the neurovascular unit responsible for the regulation of local
blood flow [109, 110]. The capillary lumen is enclosed by endothelial cells (continuous)
which are connected by tight junctions, and surrounded by basement membranes, per-
icytes, and astrocytes. Among others, pericytes support nutrition and maturation of
endothelial cells, and astrocytes are involved in e. g. inflammation control, repair pro-
cesses after CNS injury, and glial scar creation [111]. Furthermore, interacting neurons
and microglial cells are depicted.
Endothelium in the human organism can be separated into three different types: continu-
ous, fenestrated, and discontinuous endothelium [112,113]. In contrast to discontinuous,
or fenestrated endothelium, which exhibit holes between cells (about 60 to 175 nm diam-
eter [114]), the continuous endothelium consists of cells with a continuous cytoplasm
and tight junctions between cells, ensuring a low passive permeability of ions and small
hydrophilic solutes. Each organ can exhibit different types of endothelium, depending
on the specification within an organ. Whereas e. g. glomerular capillaries need to be
permeable for water and all small solutes of the blood plasma, tubular capillaries are
only partly permeable for water, ions, or polar molecules (reabsorption of vital nutrients,
and secretion of waste products via carrier proteins) [114,115].
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Within the brain only capillaries of the circumventricular organs are composed of
fenestrated endothelium. Among others this property enables the assessment and regu-
lation of body fluid composition. The remaining CNS is infiltrated by capillaries with
continuous endothelium, forming the so-called blood-brain barrier (BBB), which is
a member of the neurovascular unit (illustrated in figure 2.5). It exhibits a very high
specification level, strictly regularising influx and eﬄux of substrates. It hence pre-
vents permeation of neurotoxic substrates, which is especially important in the CNS,
since neurogenesis in adults is limited and low [116]. Moreover, the BBB plays a role
in ion homeostasis, limitation of protein availability, proliferation, and enables immune
surveillance and response [117].
2.4.2 Transport mechanisms across the BBB
Different transport mechanisms across the BBB are summarised in [110,117,118]. Only
small, lipophilic, and neutral solutes can diffuse passively into the CNS. Due to active
removal from the CNS compartment by carrier-mediated eﬄux transporters, passive dif-
fusion can be regulated and limited. Carrier-mediated influx or bidirectional transport
enables a controlled exchange of important polar molecules, such as glucose (GLUT),
amino acids (LAT), small peptides, and others. Macromolecules such as insulin, cy-
tokines and other peptides or proteins can be transported via receptor-mediated tran-
scytosis. Non-specific transport of positively charged macromolecules can take place via
adsorptive-mediated transcytosis. Moreover a modulation of tight junctions may lead to
diffusion of polar solutes or to migration of leukocytes.
2.4.3 Pathophysiology of BBB breakdown
BBB disintegration can e. g. manifest as a mutation of tight junctions, an increased
expression of receptors, or as an activation of transporting cells in the endothelium.
Moreover, endothelial cells in general can loose their specification if the organ environ-
ment changes, as it can be the case e. g. for brain-tumour capillaries [108,119–121].
Different brain pathologies have shown to influence the BBB permeability [117]. For
patients with e. g. brain cancer [122–125], stroke [126], or acute lesions of multiple sclero-
sis (MS) [127–129], a significant opening of the BBB can be observed, enabling the pas-
sage of large molecules. As a result e. g. gadolinium- (Gd3+) based MRI contrast agents
(CA) can leak into the CNS, and thus visualise large scale BBB disruption [130]. Age
related changes [131] and chronic diseases such as e. g. Alzheimer’s, cerebral small vessel
disease, diabetes, or MS (chronic active lesions) lead to more subtle BBB alterations.
Such less severe, yet pathological small-scale BBB changes are not visible in conventional
contrast-enhanced (CE) MRI. Alternative methods have been proposed, such as the util-
isation of time dependency of CA accumulation in dynamic CE (DCE) MRI [132–135],
imaging of ultrasmall, superparamagnetic iron oxide particles (USPIO) [136], or imaging
with PET tracers [137–139].
2.4.4 Optimal radio-pharmaceutical properties for brain imaging with
PET
Optimal tracer properties for brain imaging include the following: high specific and
low non-specific binding affinity, high metabolic stability, no toxicity, and the ability to
cross the BBB. The latter mainly depends on tracer lipophilicity, molecular weight (<
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450g/mol, i. e. small molecules with small cross-sectional area), and on the susceptibility
to active eﬄux transport into the blood. BBB penetration of tracer metabolites is
undesirable and is usually low, since radio-metabolites tend to be less lipophilic than
the parent compound. Further relevant properties as summarised in [140–142] are listed
below.
• Selectivity: Ideally, a tracer should be specific only for one target. In case of
multiple targets, the relative contribution within tissue, and the tracer affinity for
each target type needs to be known.
• Affinity: A high specific binding affinity compared to the amount of non-specific
binding is desirable. Moreover a high concentration of binding sites of the target
region is essential.
• Scan duration: The choice of an optimal scan window highly depends on the
kinetics of tracer uptake in tissue. After the initial uptake phase, equilibrium be-
tween tracer concentration in tissue and in blood is reached [143]. This is followed
by a washout phase, where free plasma concentration decreases. The time after
which equilibrium is reached decreases for an elevated plasma clearance in the
periphery and local blood flow (equation (2.23)), and increases with affinity and
receptor density, but does not necessarily depend on the protein bound fraction.
• Occupancy: For diagnostic use the injected amount of radio-pharmaceutical com-
pound should be low, i. e. the occupancy of binding sites should be negligible in
order to preserve linearity.
• Delivery: Tracer delivery at the tissue of interest is described by the (plasma)
input function and the respective plasma clearance. A high clearance results in a
reduced brain uptake and an early onset of washout phase. If tracer affinity and
BBB permeability are high enough a high clearance is preferred due to the reduced
measurement time-window.
• Lipophilicity (logP 1.5-4): A high tracer lipophilicity leads to an increased brain
penetration, but also to an elevated level of non-specific binding, and a higher
fraction of tracer bound to plasma proteins (lower free fraction, i. e. reduced tracer
availability). Since these effects might be contradictory, a reliable prediction of
BBB penetration and levels of non-specific binding is challenging [108, 144, 145].
Also, in vitro properties of radio-tracers need not to be predictive of in vivo char-
acteristics [146].
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Chapter 3
Studies
3.1 Objectives of this thesis
For the non-invasive assessment of central nervous system diseases, imaging of morpho-
logical and functional tissue properties is of major interest. The provided information on
CNS pathophysiology is highly relevant for diagnosis, treatment planning, and predic-
tion of treatment response, disease progression, or recurrence. The objective of this work
was the evaluation of methodological aspects relevant for quantification in brain PET
imaging, the development of advanced image processing techniques, and an application
for non-invasive characterisation of lesions in multiple sclerosis and glioma patients.
For the evaluation of lesion segmentation methods and PET signal within lesions,
preliminary phantom experiments were conducted with a NEMA NU 2-2001 spheres
phantom (section 3.2). This included an assessment of mean and maximal recovery co-
efficients for true sphere volumes depending on volume, signal-to-background ratio, and
on the reconstruction algorithm. Various threshold-based segmentation strategies were
investigated, aiming to yield true object boundaries. For this, the boundary-reproducing
thresholds were expressed in terms of different segmentation approaches. Moreover, im-
age noise properties were evaluated and described with a noise model.
The first study (publication attached in chapter 4) is described in section 3.3 and
deals with quantification approaches for TSPO imaging with 18F-GE-180 in patients with
multiple sclerosis. The main methodological challenges include the definition of a pseudo-
reference region in order to provide inter- and intra-subject comparable quantitative
parameters and to avoid invasive arterial blood sampling. This was established by first
choosing an anatomically defined region which is least affected by disease and minimises
variability among healthy controls, and then excluding voxels from this region suspected
to be affected by disease. Segmentation based on maximal and background activity
as established in phantom experiments was applied for lesion segmentation, enabling a
quantification based on mean and maximal parameters. Anatomically defined tissue and
lesion quantification based on static SUV ratios (section 2.2.4) was compared to results
from pharmacokinetic modelling.
In the second study (publication attached in chapter 5) with dynamic 18F-FET PET
data voxel-wise parametric information was employed for non-invasive glioma charac-
terisation. In addition to the published results evaluating the diagnostic accuracy of
percentage volume histograms derived from heuristic parameters (section 2.2.4), addi-
tional results are presented in section 3.4. Intensity, histogram, and texture parameters
were derived from parametric images, and pharmacokinetic modelling parameters from
30 3. Studies
average VOI TACs were related to the established heuristic parameters. The capabil-
ity to distinguish molecular genetic and histologic glioma grades was assessed for all
extracted features.
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3.2 Preliminary phantom studies: evaluation of image qual-
ity and comparison of threshold-based segmentation
methods
3.2.1 Background
In order to evaluate the quality of PET data, i. e. the signal recovery and noise properties,
and to assess the reliability of volume segmentation methods, several measurements
were performed with the NEMA NU 2-2001 spheres phantom. A summary on different
segmentation methods is given in section 2.3.1. The aim of this investigation was to
characterise and identify the most suitable segmentation method for each processing
task being performed in the subsequent studies.
3.2.2 Material and methods
Imaging
All scans were acquired in list-mode on a Biograph 64 PET/CT device (Siemens Health-
ineers, Erlangen, Germany) [147] with a scan duration of 20 minutes. Image recon-
struction was performed with FBP, OSEM2D, OSEM3D, and PSF-based OSEM3D
(TrueX). Sinograms for FBP and OSEM2D reconstruction were calculated by Fourier
rebinning [148]. Reconstruction with FBP included a 4.9 mm Hann filter. OSEM2D and
OSEM3D reconstructions were performed with a Gaussian post-reconstruction filter (4
mm FWHM). Iterative reconstruction included 4 iterations with 8, 16, and 21 subsets
(equivalent number of iterations: 32, 64, and 84).
SBR BG (kBq/mL) Spheres (kBq/mL)
30 1.4 42
15 1.4 21
8 1.4 10
8 2.9 24
6 3.0 18
4 3.7 15
2 6.4 13
Table 3.1: Signal-to-background ratios (SBR) for the used background (BG) and sphere
concentrations.
Evaluation of recovery coefficients and volume segmentation methods
Recovery coefficients (RC) of mean and maximum activity were calculated for true
sphere volumes as the ratio between image-derived and true activity concentration. The
sphere diameters of the NEMA NU 2-2001 phantom are: 37, 28, 22, 17, 13, and 10 mm.
Background and spheres were filled homogeneously with the activity concentrations listed
in table 3.1. A reconstruction-specific calibration was applied in order to obtain 100%
recovery for activities measured in the BG VOI.
Different threshold-based segmentation methods were evaluated, aiming to delineate
true volumes. In the following such thresholds will be referred to as boundary re-
producing thresholds (BRT). The optimal BRTs were extracted automatically from
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phantom data with an iterative algorithm, which compares the current volume with the
given true volumes at each iteration step.
Segmentation strategies included (1) simple thresholds relying only on maximal or
mean signal within the volume (BRT ≈ Fmax/mean · Imax/mean), or (2) on background
signal of the surrounding tissue (BRT ≈ FBG · IBG), and (3) thresholds taking both
properties into account:
BRT ≈ (Imax/mean − IBG) · FBG,max/mean + IBG. (3.1)
By applying iterative algorithms, a threshold dependency on the lesion volume can be
taken into account (assuming sphericity). This will be exemplarily incorporated for
evaluation of segmentation results obtained with FBG,mean.
Noise properties in terms of coefficient of variation
Coefficients of variation (COV) were measured in homogeneous background for varying
activity concentrations (table 3.1), and described by a theoretical noise model. For this,
it was assumed that the image statistics can be described by a Gaussian distribution
N (µ = A˜, σ =
√
A˜) (see sections 2.1.2 and 2.1.3), where A˜ is the total number of counts
(accumulated activity) within a time frame [t1, t2] (with equation (2.5)):
A˜ =
∫ t2
t1
A0 · e−λtdt
=
A0
λ
· (e−λt1 − e−λt2).
(3.2)
The measured image statistics can be estimated based on the above assumptions and a
constant scaling factor a with the following equation:
COV = a ·
√
A˜
A˜
= a · 1√
A˜
. (3.3)
3.2.3 Results
Evaluation of signal recovery and volume segmentation methods
Figure 3.1 shows the measured RC and BRT data depending on sphere volume (1st
column), number of equivalent iterations (2nd column) and SBR (last column). Recovery
was comparable for FBP and OSEM2D/3D reconstruction: RCs were not sensitive to
the number of equivalent iterations, and RCmax values were approximately equal to
1 for larger spheres (figure 3.1a). PSF-based reconstruction (TrueX) yielded slightly
higher RCmean, and RCmax values were above 1, with discontinuous behaviour for small
spheres. In general RCmean increased slightly for SBR values below 8, while RCmax
showed non-linear behaviour in case of OSEM reconstruction, and decreased in case of
TrueX reconstruction.
3.2 Preliminary phantom studies: evaluation of image quality and
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Figure 3.1: a Recovery coefficients (RC) obtained from mean (dashed lines) and max-
imum (solid lines) activities, and optimal thresholds reproducing true sphere volumes
expressed in terms of: b FBG,max/mean (equation (3.1)), c fraction Fmax/mean of max-
imal/ mean signal, and d fraction FBG of background signal. Dependency of recovery
coefficients and representations of boundary reproducing thresholds on sphere volume
(1st column), number of equivalent iterations during reconstruction (2nd column), and
signal-to-background ratio (3rd column). Results are presented for FBP, OSEM2D,
OSEM3D, and TrueX reconstructions.
The optimal threshold showed a dependency on sphere volume for all included seg-
mentation methods (figure 3.1b–d), which was most pronounced for small volumes.
FBG,mean, and Fmean decreased with increasing volume. FBG,max, and Fmax were approx-
imately constant for larger spheres, and presented with non-linear behaviour for spheres
smaller than 3 mL. FBG showed a continuous increase with sphere volume, saturating
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for larger spheres. While FBG,max/mean and Fmax/mean were approximately independent
of the number of equivalent iterations, FBG showed an increasing behaviour. The low-
est dependency on SBR was found for FBG,max/mean values. Fmax/mean was decreasing
with increasing SBR values, which was most pronounced for PSF-based reconstruction
(TrueX). However, the strongest dependency on SBR values was found for FBG.
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Figure 3.2: Comparison of different volume segmentation methods, exemplarily shown
for OSEM2D reconstructed images with 4 mm Gaussian filter and 32 equivalent itera-
tions. Estimated diameters of segmented VOIs in comparison to true sphere diameters:
a FBG,max = 0.35, b iterative FBG,mean(V ), c FBG = 1.6, d Fmax = 45%, e Fmax = 55%,
and e Fmax = 90%.
The estimated VOI diameters obtained by applying the different segmentation meth-
ods are exemplarily shown in figure 3.2 for OSEM2D reconstruction with a 4 mm Gaus-
sian filter and 32 equivalent iterations. An average fixed FBG,max threshold was calcu-
lated for the three largest spheres, and all SBRs except the lowest SBR of 2. For iterative
segmentation the dependency of FBG,mean on the sphere volume (V ) was estimated by
fitting the following equation to the measured phantom data: FBG,mean(V ) = a·e−b·V +c.
A theoretical curve might also be obtained by convolving the activity distribution within
spheres of varying size with the PSF [83] (see section 2.1.5). Both FBG,max/mean meth-
ods yielded reliable volume estimates for all sphere sizes and SBRs (figures 3.3a and
b). As expected, the volume estimation with FBG showed a strong SBR dependency
(figure 3.2c). A good correspondence between volumes segmented with Fmax = 45%
and true volumes was found for SBR > 6 (figure 3.2d). However, for SBR values below
5 the threshold defined by 45% · Imax seemed to approach the background level, which
resulted in a strong overestimation for all segmented volumes. In case of Fmax = 55%
this issue was still relevant, however only for the three smallest spheres with SBR = 2
(figure 3.2e). VOI diameters obtained with Fmax = 90% underestimated true diameters,
and showed a dependency on SBR (figure 3.2f).
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Noise properties in terms of coefficient of variation
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Figure 3.3: Coefficient of variation (COV) measured for varying background concentra-
tions and different image reconstruction methods (markers), and model representation
according to equation (3.3) (lines).
As can be seen in figure 3.3, the noise model described by equation (3.3) fits the measured
COV values well. The highest noise could be found in images reconstructed with FBP,
followed by OSEM2D images. The best noise properties were found for OSEM3D data
[149, 150]. As expected noise increased with the number of iterations. Not shown are
COV data for PSF-based reconstruction (TrueX) without additional filtering (”allpass”),
which were comparable to data from OSEM3D reconstruction with a Gaussian filter with
4 mm FWHM (i. e. lower noise level with PSF-based reconstruction).
3.2.4 Discussion
Contrast-based segmentation methods yielded the most robust and accurate results for
the estimation of true boundaries in case of spherical and homogeneously filled lesions.
Hence, this was applied for the delineation of focal MS lesions in the first publication
(chapter 4). For the definition of glioma volumes, a threshold based on FBG = 1.6 has
been previously established and validated with stereotactic biopsies [151]. The presented
phantom measurement results indicate, that the segmented lesion volumes exhibit a SBR
dependency. This results in an overestimation of lesion volumes for SBR larger than 4,
and an underestimation for smaller SBR values. For an encompassing 3D definition of
tumour tissue additional simulation experiments or studies incorporating stereotactic
biopsies should be performed.
The validated noise model might be utilised e. g. for analytical simulation of PET
data by taking into account the imaging PSF [17] and the described noise properties
with A0,noise = A0(1 + COV · N (0, 1)) (sections 2.1.3 and 2.1.5). The simulation of
PET data either with analytical, or Monte Carlo-based methods is an important tool
for the validation of various image processing and quantification steps, such as e. g. the
segmentation of non-spherical objects. Logan et al. [69] applied a similar model for
validation of a method aiming to reduce noise influence in graphical analysis with Logan
plots.
PSF-based OSEM3D reconstruction appeared to enhance lesion detectability, how-
ever at the cost of a higher risk of false positives. In line with previous studies [152,153],
a non-linear behaviour for sub-centimetre lesions could be observed (figure 3.4) [20]. To
overcome the non-linear behaviour of maximal values within small lesions, an additional
smoothing filter might be applied during PSF-based OSEM3D reconstruction. A sys-
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tematic comparison of lesion detection and quantification properties for reconstruction
with and without PSF inclusion is desirable. Future studies should include phantom or
simulation data of sub-centimetre lesions.
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Figure 3.4: Discontinuous behaviour of RCmax for small spheres in case of PSF-based
reconstruction (TrueX) shown exemplarily for varying SBR values and reconstruction
with a 32, and b 84 equivalent iterations.
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3.3 Evaluation of quantification issues of TSPO PET imag-
ing with 18F-GE-180 in patients with relapsing-remit-
ting multiple sclerosis
3.3.1 Background
The chronic autoimmune disorder multiple sclerosis (MS) is characterised by CNS in-
flammation, demyelination, and neurodegeneration. The mean age at diagnosis is about
38 years, and incidence is higher for women, and increases with latitude [154,155]. Sev-
eral genetic and environmental aspects were identified as risk factors, while e. g. vitamin
D is suspected to be protective [156].
It is hypothesised, that the peripheral immune system (activation by extrinsic anti-
gens) is most relevant in the early phase of relapsing-remitting MS (RRMS), causing
acute focal MS lesions, detectable with CE MRI. Acute active MS lesions are comprised
of activated T and B lymphocytes, macrophages, and microglia. In early stages the
disease is characterised by demyelination, followed by repair processes (remyelination)
and scar creation. In progressive MS (PMS) the local (innate) immune system of the
CNS becomes more important, resulting in an widespread global CNS inflammation,
and an increased degeneration of neuronal axons promoted by the pro-inflammatory
reaction (production of neurotoxic factors) of activated microglia together with blood-
borne macrophages. Chronic active lesions of progressive disease expand slowly, whereby
microglia and macrophages build a ring around the lesions.
Diagnosis and staging of MS
Diagnosis and staging of MS predominantly relies on a precise documentation of clinical
and paraclinical information, and of spatio-temporal development as assessed by different
MR protocols [130]. A summary on diagnostic strategies based on MR-imaging can be
found in [157]. As previously discussed by Absinta et al. [129], the correlation of MRI
findings with clinical phenotype or course of disease remains poor. For a more direct
visualisation of disease activity, specific molecular imaging (PET) tracers were developed.
This includes e. g. tracers targeting the 18-kDa translocator protein (TSPO), which is
up-regulated in activated microglia. TSPO expression can also be found on the outer
mitochondrial membrane of astrocytes, endothelial cells, infiltrating macrophages, and
tumour cells. A summary on different TSPO tracers and applications for imaging of MS
is given in [158,159].
Methodological challenges of TSPO PET
Encompassing reviews on the methodological challenges of TSPO quantification were
published e. g. by Hinz and Boellaard [160] and Turkheimer et al. [161]. The main
aspects and approaches thereof are listed below.
• The first generation TSPO tracer 11C-(R)-PK11195 was extensively investigated
for a large variety of disease conditions [159,162]. The main drawback of this tracer
was the low signal-to-background ratio and the low BBB penetration, which lead
to the development of various second generation tracers targeting TSPO.
• The second generation TSPO tracers aiming to enhance binding affinity, have
shown to be sensitive to a single nucleotide polymorphism in the TSPO gene
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(rs6971), which causes differences in binding affinities. As described in chapter 4,
individuals can be labelled as low-, medium-, or high-affinity binders (LAB, MAB,
HAB) [163–165].
• Another aspect is the high protein binding, which may cause variability among
subjects. Also, an increased signal from TSPO at the BBB is observed, limiting
the availability in tissue, and the detectability of increased activation in tissue [166].
• In order to avoid continuous blood sampling and an elaborate – and yet error prone
– analysis of metabolite fraction and fraction bound to proteins, it is desirable to
perform quantification based on information from reference tissue data. However,
an anatomically defined reference region without TSPO binding sites but similar
non-specific binding (section 2.2.3) does not exist in the CNS. Yet, if a brain
region exists, in which TSPO expression in not affected by disease, such a reference
region may potentially yield BPapparent estimates, which correlate with true BPND
(if other confounding effects such as age, gender etc. are neglected). Several
data-driven, and supervised clustering approaches have been proposed, aiming to
extract unaffected cortical voxels [73,89,167–169]. However, those methods rely on
dynamic PET data, and in some applications affected voxels could not be excluded
sufficiently [170,171].
Outline
The first publication attached in this thesis (chapter 4) aimed to evaluate quantification
methodology for the third generation TSPO tracer 18F-GE-180 in RRMS patients. This
included (1) the extraction of a pseudo-reference region, (2) the segmentation of small
lesions based on preliminary phantom measurements (section 3.2), and (3) the valida-
tion of a quantification approach utilising late summation images. Here, supplementary
results on pharmacokinetic modelling are presented, which were obtained with an IDIF
rescaled and corrected based on a limited number of discrete blood samples.
3.3.2 Material and methods
Patients and imaging
The details on patient characteristics and imaging properties can be found in the methods
section of the first publication attached in this thesis (chapter 4) [172]. Supplementary
results obtained with pharmacokinetic modelling with blood input function will be pre-
sented for a sub-group of 7 RRMS patients. For the extraction of a continuous whole
blood IF a previously described method was applied, which relies on an image-derived
activity concentration within the carotid arteries and a scaling based on manual blood
samples [53] (section 2.2.1). The method utilises dynamic scans reconstructed with
OSEM3D taking into account the imaging system PSF (PSF3D: 4 iterations, 16 subsets,
no filter, TrueX, Siemens Medical Solutions, Erlangen, Germany).
Anatomical brain regions, reference tissue extraction, and segmentation of
lesions
Anatomical brain regions were defined as described in chapter 4 and section 2.3.2. The
methodological details for the extraction of a pseudo-reference region (PRR) and
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for lesion segmentation are presented in the methods and results sections of the first
publication (chapter 4) [172]. In brief, we aimed to identify the anatomically defined
region which exhibits the lowest fraction affected by disease and which minimises vari-
ability among healthy subjects. Assessment of voxel-wise differences was performed with
statistical parametric mapping (section 2.3.3).
Lesions were assumed to be spherical, and segmented with a threshold based on
maximal and background uptake as established and validated in the phantom study
presented in section 3.2.
Blood sampling
Manual arterialised venous blood samples were taken at 5, 15, 30, 60, and 85 min p.i.
for 7 RRMS patients (BS-subgroup) [173]. Separation of plasma from blood cells was
achieved by centrifugation of the whole blood samples (3000g). The determination of
plasma-to-blood ratio and metabolite analysis were performed on blood samples taken at
5, 15, and 30 min p.i.. Activity concentration of whole blood and plasma was measured
with a gamma counter (Cobra Quantum 5002, Packard), which was cross-calibrated
with the PET device via dose calibrator (Veenstra Instruments, Netherlands), and de-
cay corrected to time of injection. For protein precipitation, plasma samples were diluted
with ice cold acetonitrile (1:4) and centrifuged (16000g) for 3 min. Blood sample ac-
tivity concentrations were below our calculated HPLC detection limit of 33 kBq/mL.
Therefore, the fraction of metabolised tracer in supernatant was evaluated with thin
layer chromatography (silica gel TLC plate, EtOAc/EtOH 4:1; Macherey-Nagel, Du¨ren,
Germany) [174,175].
Input function
The arterial input function for modelling was obtained with manual blood samples
in combination with an IDIF from PSF3D images as validated by Mourik for 11C-
(R)PK11195 [53]. The first frames during which arterial influx into the brain is visible
were used for VOI definition in carotid arteries (”4 hottest pixels per plane” method [53]).
A bi-exponential fit was performed on the IDIF and the resulting function was then scaled
to the activity of the five whole blood samples.
This was followed by a correction for plasma-to-blood ratio and metabolites. The
plasma-to-blood ratio was approximated to be constant over time [176, 177], and the
following model function (adapted from [178]) was fitted to the measured parent fractions
in plasma:
fp(t) = (1− q2) · eq1·t + q2. (3.4)
Pharmacokinetic modelling
For each anatomical brain region of the BS-subgroup and for lesions visible in PET,
mean TACs were generated, and analysed with PMOD Kinetic Modelling tool (v3.4,
PMOD Technologies, Zurich, Switzerland). Corrected Akaike information criterion
(equation (2.19)) was applied for model comparison.
Volumes of distribution VT were determined with 1TC-VB model, reversible 2TC4k-
VB model, and Logan GA (fixed t
∗ = 20 min p.i.) using metabolite corrected plasma
input function and whole blood fraction VB (equation (2.18)). With this, the distribution
volume ratios (DVR) were calculated (section 2.2.3) and compared to simple SUV ratios
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from static 60-90 min p.i. images (SUVR60−90, section 2.2.4). The 2TC4k-VB model also
provided binding potential estimates BPND,2TC . The applicability of Logan graphical
analysis for 18F-GE-180 has been validated previously for healthy controls [176,179]. In
order to assess which compartmental model provides the best description of anatomical
VOI- and lesion-TACs, also an irreversible 2TC3k-VB compartment model was included.
Kropholler et al. [180] found compartment modelling with K1/k2 fixed to a whole
cortex value to be optimal for improved convergence in 11C-(R)PK11195 brain studies.
In this study, for each patient, K1/k2 and blood volume fraction VB were set by coupled
fitting of all anatomical brain regions [181].
Correlation of modelling parameters
BPND relative to non-displaceable uptake was derived directly from 2TC4k-VB model
parameters for the BS-subgroup (BPND,2TC = k3/k4). Since there is no reference tissue
available for 18F-GE-180, which is devoid of specific binding, the quantity of interest was
specific binding relative to healthy tissue PRR (equation (2.35)):
DVR =
VT
VT,PRR
= BPapparent + 1, (3.5)
which is smaller than BPND + 1 if BPND,PRR > 0.
The applicability of a simplified ratio-based quantification was assessed by compar-
ing SUVR60−90 values to BPND,2TC , DVR1/2TC , and DVRLogan. Pearson’s correlation
coefficients were determined for all brain tissue regions and lesions of the BS-subgroup.
3.3.3 Results
Input function
A mean plasma-to-blood ratio of 1.53±0.08 was measured. Two separable radio-labelled
metabolite clusters were identified by TLC. The averaged parent fraction of tracer in
plasma depending on time p.i. is shown in figure 3.5a. The results are consistent with
previous publications for 18F-GE-180 in human controls [176,177]. However, we observed
a higher variability between subjects and only two separable instead of three metabolite
clusters, most probably due to a lower resolution of TLC compared to HPLC. The
respective averaged parent in plasma and whole blood TACs are given figure 3.5b.
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Figure 3.5: Results from metabolite analysis, whole blood and parent in plasma time
activity curves averaged over 7 patients from BS-subgroup. a Parent fraction: measured
data (red *), fit results (mean: solid line, mean ± standard deviation: dashed lines). b
Whole blood TAC (dashed line) and parent in plasma TAC (solid line).
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Pharmacokinetic modelling
Reversible 2TC4k-VB model was preferred (lowest AICC) in 79% of anatomical VOI-
TACs, and 54% of lesion-TACs. An irreversible 2T3k-VB model was selected in 21%
of anatomical VOI-TACs, and 37% of lesion-TACs. In 9% of lesion TACs the 1TC-VB
model was preferred. Average AICC values were higher for lesion-TACs (95) compared
to anatomical VOI-TACs (66), additionally indicating that lesions are less well described
by the 2TC4k-VB model. Kinetic analysis with 2TC4k-VB model and with linearising
Logan plot yielded low volumes of distribution VT , and a non-negligible amount of specific
binding BPND,2TC in anatomical brain regions (tables 3.2 and 3.3). Average transfer
rates K1, k2, k3, and k4 (2TC4k-VB model) were 0.07 mL/cm
3, 1.6, 0.20, and 0.08 for
anatomical VOI-TACs, and 0.05 mL/cm3, 1.1, 0.29, and 0.07 for lesion-TACs.
Mean ± SD VT,1TC VT,2TC VT,Logan
PRR 0.12 ± 0.02 0.14 ± 0.03 0.17 ± 0.04
Brainstem 0.13 ± 0.04 0.19 ± 0.04 0.21 ± 0.05
Cortical GM 0.13 ± 0.03 0.16 ± 0.03 0.19 ± 0.04
Thalamus 0.14 ± 0.05 0.19 ± 0.03 0.22 ± 0.04
Cerebellar GM 0.13 ± 0.04 0.16 ± 0.04 0.20 ± 0.05
White matter 0.11 ± 0.03 0.15 ± 0.03 0.18 ± 0.03
Lesions 0.21 ± 0.07 0.26 ± 0.07 0.26 ± 0.06
Table 3.2: Volumes of distribution VT in mL/cm
3 from 1TC-VB, and 2TC4k-VB model,
and linearising Logan GA for anatomical brain regions and lesions of BS-subgroup.
Mean ± SD BPND,2TC DVR1TC DVR2TC DVRLogan SUVR
PRR 2.1 ± 0.4 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00
Brainstem 3.2 ± 0.8 1.15 ± 0.23 1.38 ± 0.29 1.27 ± 0.14 1.29 ± 0.15
Cortical GM 2.5 ± 0.4 1.13 ± 0.09 1.16 ± 0.09 1.13 ± 0.07 1.14 ± 0.07
Thalamus 3.2 ± 0.6 1.22 ± 0.22 1.36 ± 0.16 1.29 ± 0.07 1.31 ± 0.08
Cerebellar GM 2.6 ± 0.6 1.14 ± 0.12 1.17 ± 0.13 1.15 ± 0.10 1.16 ± 0.09
White matter 2.4 ± 0.3 0.99 ± 0.12 1.11 ± 0.07 1.05 ± 0.04 1.07 ± 0.04
Lesions 4.7 ± 1.5 1.73 ± 0.37 1.83 ± 0.40 1.52 ± 0.17 1.59 ± 0.12
Table 3.3: Binding potentials BPND,2TC from 2TC4k-VB model, and distribution vol-
ume ratios (DVR) from 1TC-VB, and 2TC4k-VB model, and linearising Logan GA for
anatomical brain regions and lesions of BS-subgroup.
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Figure 3.6: Scatter plots for BS-subgroup. SUVR plotted against a BPND,2TC , b
DVR2TC , and c DVRLogan. For lesions with a continuously increasing kinetic (red in a
and b), the 2TC4k-VB model was less robust in particular for lesions with a continuously
increasing kinetic (red in a and b).
Correlation with SUVR60−90 was highly significant (p < 0.001) for all parameters pre-
sented in table 3.3. The strongest correlation was found for DVRLogan (ρ = 0.96,
figure 3.6c). Lower correlation coefficients were found for BPND,2TC from 2TC4k-VB
(ρ = 0.80, figure 3.6a), DVR1TC (ρ = 0.87), and DVR2TC (ρ = 0.86, figure 3.6b).
The outliers visible in Figures 6a and 6b are lesions. This is due to the continuously
increasing kinetics of these lesions (within the 90 min scan time window), which is not
properly dealt with by the reversible 2TC4k-VB model. In contrast, linear Logan GA
with only two fit parameters, and static SUVR60−90 yielded more robust parameter
estimates (figure 3.6c).
3.3.4 Discussion
The results obtained for VT were consistent with previously published healthy control
data [176, 177, 179]. In concordance with these previous studies, we found that the
reversible 2TC4k-VB model was optimal for the quantification of brain tissue. In this
study, for lesion quantification also the reversible 2TC4k-VB model was predominantly
selected. However, in some cases an irreversible 2TC3k-VB model yielded lower AICC
values. This might be caused by the fact, that a reversible 2TC4k-VB model does not
converge well for continuously increasing TACs, as it was observed in focal MS lesions (90
min time window). Static 60-90 min imaging with a PRR-based SUVR quantification
correlated well with DVR results from full kinetic modelling.
Feeney et al. [177], and Zanotti-Fregonara et al. [179] indicated that their modelling
results failed to describe the initial sharp peak of tissue TACs, and both also reported
very low K1 values. This might give rise to the assumption, that the optimisation algo-
rithm provides a local minimum with an unfavourably low K1. Since the average parent
in plasma and whole blood TACs extracted in this study are in good correspondence to
previously published data [176,177,179], it might be reasonably assumed, that the esti-
mated micro-parameters should be in a similar range. Although the macro-parameters
are in good correspondence to the previously published data, the micro-parameters es-
timated in this study were higher. Interestingly, e. g. the eﬄux rates k2 were relatively
high especially for anatomical VOI-TACs. This might support the hypothesis, that
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18F-GE-180 is a substrate to eﬄux pumps or transporters, which causes an overall low
uptake (VT ) [176, 177, 182]. In that case, the elevated uptake observed for MS lesions
might either be caused by alterations of the BBB such as a reduced expression of ac-
tive eﬄux pumps or transporters, or due to an increase in specific binding to TSPO.
However, all modelling results need to be interpreted with caution, since model selection
criterion scores (independent of data scaling) were low in both, previously published
studies, and results presented here. Further attempts to explain the low uptake in the
CNS include an influence from a high fraction bound to plasma proteins, which however
does not necessarily affect brain penetration and was comparable to other TSPO tracers
(section 2.4.4) [179]. Moreover, 18F-GE-180 presents with favourable properties such
as a high plasma fraction, low metabolite fraction, high lipophilicity (logD at pH 7.4:
2.95 [183]), high affinity for TSPO (0.87 nM [183]), and a constantly high availability
in blood. In summary, the most likely explanation seems to be a high eﬄux rate rather
than a low BBB penetration.
It is currently controversially discussed, whether the observed elevated 18F-GE-180
signal in lesions of human glioma and RRMS patients is predominantly an effect aris-
ing due to a disruption of the BBB, or due to specific binding to TSPO independent
of a BBB disruption [172, 177, 179, 184]. Although an increased uptake could be ob-
served even in regions without CE in T1-weighted MRI images of gliomas [184], focal
MS lesions [185], and in wide-spread lesions of progressive multifocal leukoencephalopa-
thy (PML) [?], this might still be caused by subtle BBB changes resulting in a higher
availability within the CNS (section 2.4.3). Another issue discussed in literature is, that
differences between genotypes (LAB, MAB, HAB) cannot be observed in some studies
and only very weakly effects are measured by others. However, it has been reported,
that in vitro measurements by D. Owen (unpublished) revealed significant binding affin-
ity differences between MABs and HABs (displacement of 3H-PK11195 by cold GE-180).
The low or vanishing differences observed for 18F-GE-180 might be interpreted as evi-
dence for the hypothesis, that the low brain uptake is not dominated by specific TSPO
binding. However, a highly probable disagreement between in vitro and in vivo studies
was reported previously [146, 186, 187]. One further conspicuous observation is, that
both tracers (11C-(R)-PK11195 and 18F-GE-180) without striking differences between
genotypes show a higher plasma fraction (approx. 1.5) compared to other 2nd gener-
ation tracers [179, 180]. Since, it could be shown recently, that 18F-GE-180 uptake is
significantly reduced by blocking with XBD173 [?], it is highly likely, that the observed
signal in lesions is related to specific TSPO binding. The contribution of a BBB dis-
integration to maximal uptake in lesions needs to be further analysed in future studies
using perfusion weighted imaging. Also, a comparison of uptake in inflammatory lesions
measured with 18F-GE-180 and with other TSPO tracers would be desirable.
Another matter of current debate is the applicability of reference tissue methods for
TSPO tracers. Relevant objections have been raised [188,189]. It is highly probable, that
reference tissue requirements as listed in section 2.2.3 are violated in case of a disrupted
BBB. Folkersma et al. [188] observed an increased variability of K1/k2 across the brain
in early phase after traumatic brain injury, which is suspected to reflect BBB disruption.
Depending on the severity of BBB disintegration, and the specific tracer properties it
might be recommended to validate the applicability of reference tissue quantification
with arterial sampling, in order to avoid biased BP (or DVR) estimates. Yet, under
the assumption that the reference region is not affected by disease, one advantage of
reference tissue utilisation is the inherent normalisation which has the potential to reduce
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the variability caused e. g. by patient age, gender, or genotype.
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3.4 Non-invasive glioma characterisation with voxel-based
features, shape, and pharmacokinetic modelling pa-
rameters using 18F-FET PET
3.4.1 Background
Glioma classification
According to the updated (2016) WHO guideline on the classification of tumours of the
CNS, tumour classification is no longer based only on histology (phenotype), but partic-
ularly emphasises the relevance of molecular genetic information (genotype) [190, 191].
Several studies showed that gliomas with a mutation of the isocitrate dehydroge-
nase (IDH) gene (IDH -mut) have a better prognosis than IDH -wildtype (IDH -wt)
gliomas [190,192,193]. IDH -mut gliomas can be sub-divided into gliomas which present
with a 1p/19q co-deletion, i. e. a loss of the chromosome arms 1p and 19q, or without.
Histological grades differentiate between low-grade gliomas (LGG, WHO grade II), and
high-grade gliomas (HGG) comprising WHO grades III, and IV (glioblastoma, GBM).
It could be shown, that IDH -wt gliomas are predominantly associated with an in-
creased angiogenesis. This could be detected e. g. as an elevation of relative cerebral
blood volume (rCBV) compared to healthy tissue derived with perfusion weighted MR
imaging (PWI). On the contrary, IDH -mut gliomas presented with normal, or decreased
rCBV when compared to healthy tissue [194, 195]. Similarly, relative tumour blood
flow (rCBF) was found to be significantly elevated in IDH -wt compared to IDH -mut
gliomas [196–198]. In aggressive gliomas the increased angiogenesis coincides with BBB
disintegration as described in section 2.4.3. Due to the significantly reduced survival in
gliomas with increased angiogenesis, several therapies have been developed, aiming to
reduce endothelial growth factors [196].
Amino acid PET with 18F-FET PET
As summarised by the response assessment in neuro-oncology (RANO) working group
[199] amino acid PET with 18F-FET is suspected to provide a superior diagnostic accu-
racy compared to MRI for glioma grading, detection of recurrence, assessment of treat-
ment response, and prognosis. Up to now, several heuristic parameters (as presented in
section 2.2.4) have shown clinical relevance [200–204].
While a clinical relevance has been proven, the underlying physiological processes
and differences in tissue properties affecting dynamic 18F-FET PET uptake in healthy
and tumoural tissue are still under investigation. Until now, it could be shown that
the fraction of 18F-FET bound to plasma proteins is low, and that 18F-FET has a
high in-vivo stability and exhibits low uptake in inflammatory tissue [205, 206]. Since
18F-FET is large, it is suspected to be transferred via specific amino acid transporters
(AAT), such as the system L. The exact mechanisms are however still controversially
discussed [207–211]. For rats with implanted human glioblastoma cells no significant
difference in TBR and late slope could be found before and after a therapeutic reduction
of BBB permeability [212] .
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Outline
In addition to the published voxel-based percentage volume histogram data (chapter 5),
here the results obtained for further histogram, shape, texture, and pharmacokinetic
modelling parameters are presented (section 2.3.4). For all parameters the ability to
differentiate IDH -wt from IDH -mut gliomas, and HGG from LGG gliomas was assessed.
Additionally, a preliminary attempt was made to perform pharmacokinetic modelling,
in order to improve the understanding of the established heuristic parameters.
3.4.2 Material and methods
Patients and imaging
Dynamic 18F-FET PET scans of 162 newly diagnosed glioma patients were included in
this study. The details on patient characteristics and imaging properties can be found in
the methods section of the second publication attached in this thesis (chapter 5) [213].
VOI delineation
Although a delineation of biological tumour volumes (BTV) based only on activity con-
centration in surrounding tissue (BG) has proven to be unfavourable for the delineation
of true object boundaries (section 3.2.3), this is the commonly applied and established
method, which has been validated with stereotactic biopsies by Pauleit et al. [151]. In
that study, a TBR threshold of 1.6 yielded optimal sensitivity and specificity for distin-
guishing tumoural from healthy tissue in static 15-40 min p.i. images. Albert et al. [203]
showed that late 20-40 min p.i. scans are less suitable for glioma grading than early
static scans. Hence, static 20-40 min p.i. scans were utilised for tumour delineation, as-
suming to yield reliable BTV estimates independent of glioma grade. For the VOI-based
extraction of TTP and Slope15−40, additionally a 90% isocontour was applied on static
10-30 min p.i. images [202].
Extraction of histogram, texture, and shape parameters
All parameters were extracted automatically with an in-house developed software which
is written within the ROOT data analysis framework (version 6.09/01, Cern, Switzer-
land), and includes algorithms provided by the ITK segmentation and registration toolkit
(version 4.11, National Library of Medicine). Histogram and texture analysis was per-
formed on TTP, Slope15−40, TBR5−15, TBR10−30, and TBR20−40 images. For this, the
intensity values were discretised with a fixed bin size. In contrast to a fixed number of
bins per volume, this has shown to provide a superior inter- and intra-patient compara-
bility of the extracted parameters [104, 105]. The chosen fixed bin width for TBR data
was 0.05, for TTP 1 min, and for Slope15−40 the bin width was set to 0.12 SUV/h.
The definitions of the applied histogram, texture, and shape features can be found
in section 2.3.4. In addition to the standard deviation of enclosed intensity values,
the following parameters were extracted from histogram data (ROOT class TH1 [214]):
PVH, skewness, kurtosis, uniformity, and entropy. Feature extraction based on the grey
level co-occurrence matrix in ITK (class: ”HistogramToTextureFeaturesFilter” [215])
provided the following parameters: energy, entropy, correlation, inverse difference mo-
ment, inertia, cluster shade, cluster prominence, and Haralick’s correlation. The follow-
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ing shape parameters were obtained (ITK class ”ShapeLabelObject” [216]): elongation,
roundness, equal sphere radius, flatness, mesh volume, and mesh area.
Pharmacokinetic modelling
Since no blood sampling was performed during dynamic 18F-FET PET scans in this ret-
rospective study, pharmacokinetic modelling had to rely on a whole blood IDIF without
the application of re-scaling, or correction for plasma-to-blood ratio and metabolites.
Previous studies indicate, that the plasma-to-whole blood ratio is constant and parent
fraction decreases very slowly during the scan duration [205]. The influence of metabolite
correction on reference tissue-based DVRs has shown to be negligible [217]. Average tis-
sue TACs were extracted from the BTV. The FOV of the dynamic PET images acquired
for this study was too small for a reliable IDIF extraction from the carotid arteries.
Therefore, the VOI was placed in the sinus sagittalis superior. The ”4 hottest pixels
per plane method” [53] was applied for the definition of the blood VOI, and compared
to an 55% iso-contour. 20 consecutive planes were included starting from the confluens
sinuum.
The following compartmental models were included: 1- and 2-tissue compartment
models (equations (2.28) to (2.30)) with and without the inclusion of a blood volume
fraction Vb (equation (2.18)). In addition to the reversible 2TC model (2TC4k), also an
irreversible (2TC3k) model, linear models with blood input (section 2.2.2), or reference
tissue input (section 2.2.3) were evaluated.
Fitting of the model equations was performed by minimising the WRSS as defined
in equation (2.20) within the ROOT framework (class ”TGraphErrors” and Minuit min-
imizer). The frame weights in this study were set to wf =
1
∆tf
, enabling an equal
weighting of each time point, i. e. independence from the frame lengths ∆tf . Compart-
mental models with blood input were compared using the corrected Akaike information
criterion (equation (2.19)).
Statistical analysis
The ability to differentiate molecular genetic and histologic glioma grades was assessed
using the areas under the curve (AUC) of receiver-operating characteristics (ROC) anal-
ysis, and the p-values and effect sizes derived from Mann-Whitney U -test. The effect
size was defined as r = |test statistic|/sample size.
3.4.3 Results
Differentiation of glioma grades
Tables 3.4 to 3.7 summarise the results obtained with conventional heuristic VOI-based
parameters (section 2.2.4), published voxel-based percentage volume histogram data, and
additionally results obtained for further histogram, shape, texture, and pharmacokinetic
modelling parameters. The highest AUCs for the identification of IDH -wt gliomas were
found for PVHSlope,15−40<0, PVHTTP<20, net influx rates (Ki, and Ki/VT,Ref ) from Pat-
lak GA, and intercepts of GA. The highest AUC for distinguishing HGG from LGG was
found for PVHTBR,5−15>2. Shape parameters yielded low AUC values, with best results
for lesion size related parameters (equal sphere radius, volume and mesh surface area).
Texture features derived from different parametric maps tended to provide the highest
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AUC values for features from TTP and TBR5−15 maps. For example homogeneity of
TBR5−15 values decreased with increasing aggressiveness.
IDHwt from IDHmut . HGG from LGG    .Median      .
AUC U-test, p effect AUC U-test, p effect BG IDHmut IDHwt LGG HGG
90% isocontour
TTP (min) 0.75 0.000 0.44 0.72 0.000 0.38 35 25 17 25 17
Slope15-40 (SUV/h) 0.75 0.000 0.44 0.71 0.000 0.35 0.25 -0.01 -1.04 0.02 -0.77
Conventional BTV 
data
TTP (min) 0.77 0.000 0.49 0.73 0.000 0.39 35 35 25 35 25
Slope15-40 (SUV/h) 0.82 0.000 0.55 0.77 0.000 0.45 0.24 0.56 -0.13 0.57 0.05
TBR5-15,max 0.71 0.000 0.37 0.77 0.000 0.44 1.53 2.78 4.03 2.65 3.90
TBR5-15 0.76 0.000 0.45 0.80 0.000 0.50 1.00 1.82 2.36 1.76 2.30
TBR20-40,max 0.61 0.016 0.19 0.71 0.000 0.34 1.39 2.70 3.28 2.56 3.36
TBR20-40 0.60 0.023 0.18 0.72 0.000 0.35 1.00 1.92 2.05 1.86 2.06
SUV20-40 0.59 0.052 0.15 0.62 0.010 0.20 1.02 1.91 2.09 1.96 2.15
Table 3.4: Results of conventional VOI-based parameters. Areas under the ROC curve
(AUC), and U -test p-values and effect sizes are presented for distinguishing IDH wt from
IDH mut gliomas, and HGG from LGG. AUC values are shown colour-coded (white-
yellow-red continuously scaled from AUC= 0.5 to AUC= 0.8). Median parameter values
of healthy background tissue (BG), and molecular genetic, and histologic glioma groups
are given on the right.
    IDHwt from IDHmut            . HGG from LGG                     . Median                                                                                  . 
    AUC U-test, p effect AUC U-test, p effect BG IDHmut IDHwt LGG HGG 
PVH 
TTP < 20 0.83 0.000 0.58 0.79 0.000 0.47 0.43 0.21 0.59 0.19 0.50 
Slope15-40 < 0 0.84 0.000 0.58 0.78 0.000 0.45 0.07 0.22 0.56 0.21 0.47 
TBR5-15 > 2 0.80 0.000 0.52 0.82 0.000 0.53 0.00 0.28 0.69 0.19 0.66 
TBR20-40 > 2 0.60 0.022 0.18 0.72 0.000 0.35 0.00 0.31 0.45 0.23 0.46 
Skewness 
TTP 0.83 0.000 0.58 0.75 0.000 0.42 -0.25 -0.69 0.27 -0.75 0.07 
Slope15-40 0.47 0.551 0.05 0.62 0.012 0.20 0.00 -0.09 -0.04 0.02 -0.09 
TBR5-15 0.56 0.176 0.11 0.59 0.067 0.14 -0.17 0.41 0.51 0.42 0.51 
TBR10-30 0.58 0.077 0.14 0.60 0.038 0.16 -0.22 0.52 0.60 0.52 0.60 
TBR20-40 0.54 0.435 0.06 0.46 0.355 0.07 -0.20 0.88 0.92 0.92 0.88 
Kurtosis 
TTP 0.56 0.214 0.10 0.58 0.080 0.14 -1.04 -0.57 -0.73 -0.48 -0.69 
Slope15-40 0.45 0.300 0.08 0.57 0.172 0.11 0.04 0.09 0.00 0.07 0.05 
TBR5-15 0.45 0.269 0.09 0.44 0.206 0.10 0.06 0.01 -0.19 -0.01 -0.16 
TBR10-30 0.50 0.987 0.00 0.46 0.403 0.07 0.09 -0.09 -0.11 -0.11 -0.10 
TBR20-40 0.54 0.373 0.07 0.46 0.411 0.06 0.15 -0.06 0.18 0.20 0.05 
Standard deviation 
TTP 0.59 0.047 0.16 0.66 0.001 0.26 9.80 8.02 8.44 7.80 8.43 
Slope15-40 0.64 0.003 0.23 0.69 0.000 0.31 0.63 0.80 0.93 0.76 0.93 
TBR5-15 0.70 0.000 0.34 0.76 0.000 0.43 0.17 0.32 0.55 0.25 0.53 
TBR10-30 0.66 0.001 0.27 0.75 0.000 0.40 0.14 0.28 0.44 0.23 0.44 
TBR20-40 0.61 0.019 0.18 0.71 0.000 0.35 0.13 0.24 0.36 0.21 0.39 
Uniformity 
TTP 0.79 0.000 0.51 0.77 0.000 0.44 0.23 0.36 0.24 0.36 0.25 
Slope15-40 0.65 0.001 0.25 0.71 0.000 0.34 0.05 0.04 0.04 0.05 0.04 
TBR5-15 0.71 0.000 0.36 0.78 0.000 0.46 0.08 0.04 0.03 0.06 0.03 
TBR10-30 0.67 0.000 0.29 0.76 0.000 0.42 0.10 0.05 0.03 0.06 0.04 
TBR20-40 0.60 0.023 0.18 0.71 0.000 0.35 0.11 0.07 0.05 0.09 0.05 
Entropy 
TTP 0.79 0.000 0.50 0.77 0.000 0.44 2.29 1.77 2.28 1.67 2.17 
Slope15-40 0.64 0.002 0.25 0.71 0.000 0.34 4.43 4.73 4.97 4.67 4.95 
TBR5-15 0.70 0.000 0.35 0.77 0.000 0.44 3.81 4.65 5.34 4.36 5.30 
TBR10-30 0.66 0.000 0.28 0.75 0.000 0.41 3.52 4.45 5.05 4.21 5.02 
TBR20-40 0.60 0.022 0.18 0.72 0.000 0.36 3.38 3.96 4.53 3.69 4.57 
Table 3.5: Results of histogram-based parameters. Data are presented as described for
table 3.4.
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IDHwt from IDHmut . HGG from LGG                      . Median .
AUC U-test, p effect AUC U-test, p effect BG IDHmut IDHwt LGG HGG
GLCM Energy
TTP 0.79 0.000 0.50 0.76 0.000 0.43 0.076 0.178 0.087 0.199 0.097
Slope15-40 0.64 0.003 0.24 0.71 0.000 0.35 0.004 0.003 0.002 0.004 0.002
TBR5-15 0.71 0.000 0.36 0.79 0.000 0.47 0.014 0.006 0.002 0.007 0.002
TBR10-30 0.67 0.000 0.30 0.76 0.000 0.43 0.019 0.005 0.002 0.008 0.003
TBR20-40 0.62 0.007 0.21 0.73 0.000 0.37 0.020 0.007 0.003 0.011 0.004
GLCM Entropy
TTP 0.79 0.000 0.50 0.77 0.000 0.44 4.34 3.18 4.12 3.05 3.96
Slope15-40 0.63 0.004 0.23 0.70 0.000 0.33 8.41 8.59 9.06 8.49 9.01
TBR5-15 0.70 0.000 0.34 0.78 0.000 0.46 6.58 7.81 9.20 7.57 9.14
TBR10-30 0.67 0.000 0.29 0.76 0.000 0.42 6.20 7.79 9.01 7.38 8.86
TBR20-40 0.62 0.006 0.21 0.73 0.000 0.37 6.12 7.49 8.58 7.01 8.59
GLCM Correlation
TTP 0.53 0.548 0.05 0.53 0.469 0.06 0.003 0.006 0.006 0.006 0.006
Slope15-40 0.62 0.010 0.20 0.63 0.009 0.21 0.020 0.014 0.010 0.013 0.011
TBR5-15 0.72 0.000 0.38 0.77 0.000 0.43 0.083 0.024 0.008 0.033 0.009
TBR10-30 0.68 0.000 0.30 0.73 0.000 0.38 0.107 0.022 0.009 0.035 0.009
TBR20-40 0.59 0.040 0.16 0.68 0.000 0.29 0.114 0.021 0.011 0.036 0.011
GLCM inverse 
difference moment
(Homogeneity)
TTP 0.77 0.000 0.46 0.74 0.000 0.39 0.47 0.58 0.50 0.59 0.52
Slope15-40 0.61 0.015 0.19 0.60 0.036 0.16 0.23 0.19 0.18 0.19 0.18
TBR5-15 0.76 0.000 0.44 0.78 0.000 0.45 0.41 0.27 0.18 0.30 0.19
TBR10-30 0.72 0.000 0.38 0.75 0.000 0.41 0.46 0.27 0.19 0.30 0.20
TBR20-40 0.65 0.001 0.26 0.71 0.000 0.35 0.47 0.29 0.22 0.31 0.22
GLCM inertia
(Contrast)
TTP 0.57 0.114 0.12 0.60 0.030 0.17 128.2 70.9 77.6 67.2 77.1
Slope15-40 0.61 0.013 0.19 0.63 0.009 0.20 24.3 35.7 44.2 36.4 42.6
TBR5-15 0.74 0.000 0.42 0.77 0.000 0.45 5.3 18.1 46.2 11.7 40.7
TBR10-30 0.71 0.000 0.36 0.75 0.000 0.41 3.7 16.8 39.7 11.4 37.0
TBR20-40 0.65 0.001 0.27 0.72 0.000 0.36 3.5 16.1 32.7 11.7 32.4
GLCM cluster shade
TTP 0.82 0.000 0.56 0.70 0.000 0.33 -626 -950 769 -858 315
Slope15-40 0.51 0.896 0.01 0.37 0.009 0.21 -9 -111 -62 41 -219
TBR5-15 0.64 0.002 0.24 0.70 0.000 0.32 -23 343 1957 188 1779
TBR10-30 0.64 0.002 0.25 0.72 0.000 0.35 -19 312 1610 208 1596
TBR20-40 0.62 0.009 0.21 0.71 0.000 0.34 -14 424 1749 310 1929
GLCM cluster 
prominence
TTP 0.60 0.027 0.17 0.68 0.000 0.29 132917 74293 92995 62106 93387
Slope15-40 0.64 0.003 0.24 0.71 0.000 0.34 20674 58584 104737 49573 101977
TBR5-15 0.70 0.000 0.34 0.76 0.000 0.43 2218 24644 250270 17402 232688
TBR10-30 0.66 0.000 0.28 0.74 0.000 0.40 1516 24997 195578 12181 174613
TBR20-40 0.62 0.009 0.21 0.72 0.000 0.36 1432 16953 124661 8842 133449
GLCM Haralick 
correlation
TTP 0.56 0.158 0.11 0.43 0.135 0.12 55705 49454 42843 47459 48603
Slope15-40 0.63 0.004 0.23 0.71 0.000 0.35 432849 1023555 2183645 786412 1946540
TBR5-15 0.72 0.000 0.38 0.79 0.000 0.47 39758 298573 3036900 169246 2227860
TBR10-30 0.68 0.000 0.30 0.76 0.000 0.42 27776 242184 1640760 106531 1439010
TBR20-40 0.62 0.009 0.20 0.72 0.000 0.36 26574 85512 425472 31906 418567
Shape
Elongation 0.45 0.247 0.09 0.44 0.237 0.09 3.55 1.32 1.29 1.37 1.29
Roundness 0.56 0.188 0.10 0.58 0.103 0.13 0.51 0.79 0.76 0.78 0.76
Equal sphere radius 0.56 0.188 0.10 0.68 0.000 0.29 19.6 15.1 16.2 12.7 16.9
Flatness 0.61 0.014 0.19 0.53 0.516 0.05 2.22 1.29 1.22 1.27 1.27
Volume (mL) 0.56 0.188 0.10 0.68 0.000 0.29 31.8 14.3 17.7 8.5 20.0
Mesh area (cm2) 0.57 0.104 0.13 0.68 0.000 0.29 91.7 38.3 48.7 24.5 49.4
Table 3.6: Results of GLCM-based texture features, and shape parameters. Data are
presented as described for table 3.4.
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IDHwt from IDHmut .HGG from LGG                       . Median                                                                                      .
AUC U-test, p effect AUC U-test, p effect BG IDHmut IDHwt LGG HGG
VT
1TC-VB 0.49 0.786 0.02 0.55 0.344 0.07 0.58 1.38 1.38 1.36 1.44
2TC4k-VB 0.58 0.084 0.14 0.49 0.811 0.02 0.66 1.48 1.39 1.43 1.46
Logan 0.47 0.475 0.06 0.53 0.570 0.04 0.63 1.31 1.27 1.29 1.31
RE 0.58 0.090 0.13 0.64 0.004 0.23 0.57 1.11 1.21 1.09 1.22
DVR
1TC-VB 0.49 0.867 0.01 0.63 0.007 0.21 1.00 2.31 2.33 2.24 2.39
2TC4k-VB 0.43 0.138 0.12 0.59 0.060 0.15 1.00 2.26 2.13 2.14 2.22
Logan Reference 0.58 0.090 0.13 0.65 0.001 0.25 1.00 1.95 2.05 1.89 2.06
RE Reference 0.63 0.004 0.23 0.73 0.000 0.38 1.00 1.91 2.08 1.86 2.08
Patlak
Blood input Ki 0.83 0.000 0.57 0.73 0.000 0.38 0.55 1.19 0.65 1.19 0.79
Reference Ki/VTRef 0.83 0.000 0.57 0.76 0.000 0.43 0.00 0.19 -1.14 0.40 -0.86
VB
1TC-VB 0.61 0.012 0.20 0.65 0.002 0.24 0.13 0.19 0.22 0.18 0.22
2TC4k-VB 0.63 0.005 0.22 0.70 0.000 0.32 0.09 0.13 0.16 0.12 0.16
1TC-VB
K1 0.73 0.000 0.40 0.75 0.000 0.40 0.04 0.09 0.15 0.08 0.14
k2 0.79 0.000 0.50 0.76 0.000 0.43 0.07 0.07 0.11 0.07 0.10
2TC4k-VB
K1 0.67 0.000 0.29 0.57 0.169 0.11 0.15 0.22 0.34 0.24 0.27
k2 0.59 0.043 0.16 0.42 0.095 0.13 0.96 0.54 0.65 0.67 0.55
k3 0.56 0.189 0.10 0.40 0.036 0.16 0.17 0.15 0.16 0.18 0.15
k4 0.75 0.000 0.43 0.74 0.000 0.39 0.06 0.06 0.10 0.06 0.09
VND 0.58 0.070 0.14 0.71 0.000 0.35 0.18 0.45 0.55 0.41 0.56
BPND 0.65 0.001 0.26 0.76 0.000 0.42 2.63 2.26 1.59 2.70 1.65
GA blood input 
intercepts
Logan 0.77 0.000 0.47 0.77 0.000 0.44 -11.13 -12.50 -7.75 -13.60 -9.06
RE 0.66 0.000 0.27 0.61 0.022 0.18 -4.57 -10.08 -8.35 -10.15 -8.88
Patlak 0.73 0.000 0.41 0.76 0.000 0.42 0.41 0.77 1.06 0.74 1.04
GA reference 
input intercepts
Logan 0.84 0.000 0.58 0.80 0.000 0.49 -6.67 -7.99 -4.81 -8.36 -5.45
RE 0.86 0.000 0.62 0.79 0.000 0.47 0.00 -2.13 2.27 -2.56 1.49
Patlak 0.76 0.000 0.45 0.79 0.000 0.48 1.00 1.85 2.43 1.78 2.38
Table 3.7: Results of pharmacokinetic modelling parameters. Data are presented as
described for table 3.4.
Pharmacokinetic modelling
AICC values were comparable for the application of an IDIF derived from 4 hottest
voxels per plane and the IDIF obtained with the 55% · Imax iso-contour, with slightly
lower values for the ”4 hottest voxels” method [53]. In 60% of tumour TACs, and 54% of
BG TACs the 2TC4k-VB model was preferred, followed by 2TC4k (20%, 23%), 1TC-VB
(8%, 6%), 2TC3k-VB (7%, 6%), 2TC3k (4%, 11%), and 1TC (0%, 0%).
Modelling results and AUC values of average VOI TACs are given in table 3.7.
For comparison, the data for conventional heuristic parameters are given in table 3.4.
The distribution volumes VT were significantly elevated in tumour tissue compared to
BG (p < 0.001). However, VT and VT ratios (DVR, section 2.2.3) showed only partly
significant differences between grades, and revealed low AUC values. The following
parameters increased with glioma grade: K1, VB, VND, TBR5−15, and TBR20−40. A
reduction with glioma grade was found for: Slope15−40, and TTP. Moreover, k2 form
1TC-VB, and k4 from 2TCk4-VB allowed for an identification of IDH -wt, and HGG
gliomas, and revealed comparable values in IDH -mut/ LGG gliomas and BG.
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TTP Slope15-40 TBR5-15 TBR20-40 SUV20-40
VT
1TC-VB 0.00 -0.11 -0.01 -0.04 0.01
1TC -0.02 0.02 0.45 0.58 0.69
2TC4k-VB 0.00 -0.11 -0.01 -0.04 0.01
2TC4k 0.20 0.26 0.11 0.31 0.50
Logan 0.07 0.13 0.37 0.55 0.67
RE -0.18 -0.20 0.61 0.64 0.69
DVR
1TC-VB 0.00 -0.11 -0.01 -0.04 0.01
1TC -0.11 -0.16 0.75 0.97 0.55
2TC4k-VB 0.00 -0.16 0.02 -0.06 -0.04
2TC4k 0.07 0.12 0.33 0.60 0.28
Logan Reference -0.14 -0.19 0.61 0.75 0.46
RE Reference -0.21 -0.33 0.86 1.00 0.58
Patlak
Blood input Ki 0.73 0.87 -0.52 -0.06 0.03
Reference Ki/VTRef 0.72 0.89 -0.73 -0.28 -0.26
VB
1TC-VB -0.21 -0.24 0.22 0.13 0.11
2TC4k-VB -0.28 -0.31 0.23 0.07 0.05
1TC-VB
K1 -0.56 -0.54 0.57 0.30 0.29
k2 -0.65 -0.65 0.49 0.09 0.08
2TC4k-VB
K1 -0.38 -0.34 0.33 0.17 0.18
k2 -0.16 -0.03 -0.06 -0.14 -0.10
k3 -0.20 -0.16 0.09 0.00 -0.01
k4 -0.47 -0.46 0.31 0.01 -0.01
VND 0.00 -0.11 -0.01 -0.04 0.01
BPND 0.00 -0.11 -0.02 -0.05 0.01
GA blood input 
intercepts
Logan -0.58 -0.66 0.56 0.24 0.14
RE -0.43 -0.41 -0.04 -0.40 -0.44
Patlak -0.55 -0.65 0.79 0.58 -0.03
GA reference input 
intercepts
Logan -0.58 -0.71 0.70 0.36 0.20
RE -0.78 -0.81 0.68 0.17 0.20
Patlak -0.56 -0.73 0.97 0.79 0.52
Table 3.8: Correlation of conventional heuristic parameters (table 3.4) with pharmacoki-
netic modelling parameters (table 3.7) using Pearson’s correlation coefficients r. Values
are shown colour-coded (white-yellow-red continuously scaled from |r| = 0 to |r| = 0.9).
Results obtained for the correlation of heuristic parameters with pharmacokinetic
modelling parameters are presented in table 3.8. Parameters from static images were
mainly related to VT or DVR. The correlation between SUV20−40 and VT , and between
TBR20−40 and DVR was most pronounced for 1TC model, Logan, and RE GA, however
not for compartmental models with an inclusion of VB. On the contrary, an early peak
or negative Slope15−40 were associated with an elevated K1, k2 from 1TC-VB, k4 from
2TC4k-VB, and VB. An increasing kinetic with late peak was associated with an elevated
net uptake rate Ki.
For visual comparison parametric 3D distributions are exemplarily shown for three
glioma patients (figures 3.7 and 3.8). The first patient (a) presented with a typical
IDH -wt HGG, the second (b) with an IDH -mut LGG, and the last (c) with a glioma
exhibiting a heterogeneous parameter distribution. As expected from VOI-TAC analysis,
a comparison of parametric images from 1TC-VB (figure 3.8) revealed high intensity
differences between grades for K1, k2, and VB, but not for VT . Also, a high spatial
correlation of Slope15−40 and Ki/V ′T from Patlak reference tissue model was found.
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Figure 3.7: Heuristic parameter maps as applied for PVH-based analysis (chapter 5).
Dynamic PET data were smoothed frame-wise with a spatial Gaussian filter (10 mm
FWHM) before parameter estimation. From left to right: CE MRI, TBR5−15, TBR20−40,
TTP, positive, and negative Slope15−40. a Typical IDH -wt HGG, b typical IDH -mut
LGG, and c exemplary IDH-mut codel LGG glioma with heterogeneous parameter dis-
tributions, where the hottest volume in static TBR images did not co-localise with the
hot-spots in the TTP map and in the image with negative Slope15−40.
K1        k2               VT         rVB   Patlak Ki/VT’>0  Ki/VT’<0   Log. VT         Log. DVR  
0.4 
 
 
0.0 
0.3 
 
 
0.0 
2.2 
 
 
0.0 
4.5 
 
 
0.0 
2.5 
 
 
0.0 
-2.5 
 
 
0.0 
2.2 
 
 
 0.0 
4.0 
 
 
0.0 
a 
b 
c 
Figure 3.8: Parametric maps derived with pharmacokinetic modelling. Dynamic PET
data were smoothed frame-wise with a spatial Gaussian filter (10 mm FWHM). From
left to right: K1, k2, VT , and VB relative to background from 1TC-VB model; Patlak
Ki/V
′
T (positive and negative); VT and DVR from Logan GA. Patients a, b, c and
images slices are the same as presented in figure 3.7.
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3.4.4 Discussion
In general, TTP- and Slope15−40-based parameters yielded the highest AUC values for
distinguishing molecular genetic groups, and static TBR-based parameters for distin-
guishing histological groups. Best performance was observed for PVH values quantify-
ing heuristic parameter fractions, and for parameters derived with GA. Within texture
features, the best results were obtained from TTP and TBR5−15 maps. Although the
2TC4k-VB model was predominantly preferred in tumours and healthy tissue (Akaike),
the derived modelling parameters revealed only a moderate relevance for glioma grad-
ing. The highest relevance for a differentiation of glioma grades with pharmacokinetic
models was found for K1, k2 from 1TC-VB model, k4 from 2TC4k-VB model, parameters
from Patlak plots, and intercepts of graphical methods. Since VT values were signifi-
cantly elevated compared to healthy tissue, while glioma groups were indistinguishable,
it might be preferable to perform tumour segmentation in DVR images or TBR images
derived from later static scans [217]. In order to further improve the performance for
distinguishing glioma grades, e. g. the micro-parameters from kinetic modelling might be
normalised to healthy tissue values. Moreover, after a pre-selection of relevant VOI fea-
tures (e. g. best results in univariate analysis and low correlation between parameters),
machine learning might be employed for multivariate glioma classification.
A correlation of static SUV and TBR parameters with VT and DVR was only found
for compartmental models not taking into account an additional blood-volume fraction.
TTP and Slope15−40 were predominantly related to the transfer rate from blood to tissue
K1, eﬄux rate k2 from 1TC-VB, k4 from 2TC-VB, blood volume fraction VB, and net
influx rates Ki and Ki/V
′
T . As visualised in figures 3.7 and 3.8, a high spatial correla-
tion of positive and negative Slope15−40 with Ki/V ′T from Patlak reference tissue model
was found. When both parameters are extracted from the same time interval, Ki/V ′T
derived from equation (2.36) can be interpreted as slope of the tissue TAC depending on
the cumulated counts in reference tissue, thus most probably providing a higher inter-
and intra-subject comparability. Interestingly, in case of the heterogeneous glioma the
identified sub-volume with early peak and negative slope did co-localise with the hottest
volumes in K1 and k2 images from 1TC-VB model, but not with hot-spots in static
and VT images. Another interesting observation was, that a fraction of the area with
decreased signal in CE T1-weighted MRI of the IDH -mut LGG (figures 3.7 and 3.8b)
could not be detected in static TBR images, but VT values from 1TC-VB revealed an
elevated signal compared to BG. This might indicate, that later static images poten-
tially provide a better correspondence to VT images from compartmental modelling, as
previously stated by Koopman et al. [217].
The observed differences in K1 (equation (2.23)), and VB might be partly related
to the described different angiogenic properties of IDH -mut and IDH -wt gliomas. In
line with our expectations, Go¨ttler et al. [218] showed that the correlation with peak
rCBV values from PWI was higher for Slope10−30 and early 18F-FET uptake (SUV10−20)
compared to late uptake (SUV30−40). Moreover, a significant correlation of CBF with
18F-FET uptake was found [217, 219]. In the next steps e. g. information on blood flow
and PS from PWI might be linked to K1 according to equation (2.23), and inserted in
compartmental models using continuous blood sampling. Furthermore, the estimation
of VND from blocking experiments would be desirable.
In summary, this study suggests, that the application of parametric images is of high
relevance for the identification of aggressive sub-volumes and tumour heterogeneity. The
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next steps will include parameter selection and model estimation for glioma grading
or prediction of e. g. recurrence and survival. Moreover, multi-parametric (and multi-
modal) data might be utilised for a voxel-wise generation of membership-maps for glioma
classification or of probability maps for the prediction of e. g. tumour recurrence [220].
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3.5 Conclusions and outlook
The investigated segmentation, feature extraction, and modelling approaches applied on
dynamic brain PET images of specific tracers have the potential to significantly support
the characterisation of brain pathology, and an application in clinical routine appears to
be feasible. The next steps should aim to improve the understanding of the underlying
physiologic properties and a validation of methodology. This might include the utilisa-
tion of pharmacokinetic models as an input for the simulation of activity distributions,
and a subsequent validation of methodology by simulating dynamic PET images either
with analytical, or Monte Carlo methods as implemented e. g. in the GATE simulation
toolkit [221]. Such simulation studies may also be applied for an elaborate assessment
of different voxel-based partial volume effect correction techniques (section 2.1.5) and
reconstruction algorithms, e. g. evaluating the influence on parameter estimation. Also,
the noise-properties of different reconstruction algorithms should be incorporated in
order to assess the influence of TAC-noise on voxel-wise parameter estimation. With
respect to this, it becomes highly desirable to implement and test strategies aiming to
reduce noise influence, e. g. by taking into account a spatio-temporal connectedness of
voxels [222]. This forms the basis for further elaborate analysis utilising machine learn-
ing for non-invasive assessment of heterogeneity, or a 3D prediction of lesion recurrence.
Such information is of high clinical interest, supporting e. g. planning of glioma biopsy,
surgery, or radiation therapy. Moreover, in case of diffuse neuroinflammation or neurode-
generation, a further evaluation of machine learning methods might refine the proposed
method for the definition of voxels unaffected by disease.
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Figure 3.9: Two exemplary IDH -mut HGG gliomas (patient a and b) scanned with
contrast-enhanced MRI, 18F-GE-180 PET, and 18F-FET PET. From left to right: CE
T1-weighted MRI, T2-weighted MRI, static TBR60−90 from 18F-GE-180 PET, and para-
metric images from 18F-FET PET: static TBR20−40, K1 and k2 from 1TC-VB, DVR from
Logan reference tissue model, and positive and negative Ki/V
′
T from Patlak reference
tissue model.
In order to provide a robust prediction model for glioma patients, our group currently
combines information from multi-modal data, i. e. TSPO PET, amino acid PET, and
contrast enhanced MRI. The three modalities have been found to provide complementary
information [184, 223]. Two exemplary IDH -mut HGG patients, which were scanned
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with all three modalities, are shown in figure 3.9. While static TBR20−40 from 18F-
FET PET revealed two hot-spots with similar uptake for patient (a), the lower hot-
spot was more pronounced in 18F-GE-180 PET and exhibited negative Ki/V
′
T (Patlak
reference tissue model) and contrast-enhancement in T1-weighted MRI. The upper hot-
spot revealed positive Ki/V
′
T values and a lower signal in CE MRI. The second example
glioma (b) revealed reduced signal in CE MRI, one hot-spot in 18F-GE-180 PET, two
hot-spots in static 18F-FET PET, and a heterogeneous distribution of Ki/V
′
T values. A
further incorporation of parametric information from perfusion weighted imaging and a
comparison to micro-parameters as measured with PET is desirable.
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TSPO imaging using the novel PET ligand
[18F]GE-180: quantification approaches in
patients with multiple sclerosis
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Abstract
Background: PET ligands targeting the translocator protein (TSPO) represent promising tools to visualise
neuroinflammation. Here, we analysed parameters obtained in dynamic and static PET images using the novel
TSPO ligand [18F]GE-180 in patients with relapsing remitting multiple sclerosis (RRMS) and an approach for
semi-quantitative assessment of this disease in clinical routine.
Seventeen dynamic [18F]GE-180 PET scans of RRMS patients were evaluated (90 min). A pseudo-reference
region (PRR) was defined after identification of the least disease-affected brain area by voxel-based
comparison with six healthy controls (HC) and upon exclusion of voxels suspected of being affected in static
60–90 min p.i. images. Standardised uptake value ratios (SUVR) obtained from static images normalised to PRR
were correlated to the distribution volume ratios (DVR) derived from dynamic data with Logan reference
tissue model.
Results: Group comparison with HC revealed white matter and thalamus as most affected regions. Fewest
differences were found in grey matter, and normalisation to frontal cortex (FC) yielded the greatest reduction
in variability of healthy grey and white matter. Hence, FC corrected for affected voxels was chosen as PRR,
leading to time-activity curves of FC which were congruent to HC data (SUV60–90 0.37, U test P = 0.42). SUVR
showed a very strong correlation with DVR (Pearson ρ > 0.9). Focal MS lesions exhibited a high SUVR (range,
1.3–3.2).
Conclusions: This comparison with parameters from dynamic data suggests that SUVR normalised to corrected
frontal cortex as PRR is suitable for the quantification of [18F]GE-180 uptake in lesions and different brain regions of
RRMS patients. This efficient diagnostic protocol based on static [18F]GE-180 PET scans acquired 60–90 min p.i. allows
the semi-quantitative assessment of neuroinflammation in RRMS patients in clinical routine.
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Background
The classic diagnosis of multiple sclerosis (MS) is based
on clinical and paraclinical documentation of the
dissemination of CNS lesions in time and space. Such
lesions and their evolution over time are commonly
detected by magnetic resonance imaging (MRI). This
forms not only the basis of the diagnosis but is also used
to monitor disease activity and inform the decision on
appropriate therapeutic strategies. While in MRI, the
disruption of the blood-brain barrier (BBB) is used as
proxy of disease activity, positron emission tomography
(PET) imaging of activated microglia or macrophages
with the 18-kDa translocator protein (TSPO) visualises
one of the hallmarks of neuroinflammation and thus
might provide a more direct approach to assess disease
activity in MS. TSPO is primarily expressed in activated
microglia, astrocytes, endothelial cells, and infiltrating
macrophages [1] and is therefore associated with ner-
vous system inflammation [2]. The prototypic TSPO
radioligand [11C](R)-PK11195 has been frequently inves-
tigated in various PET imaging studies [3]. However,
quantification with [11C](R)-PK11195 has been shown
to be challenging due to a low free fraction in
plasma, a significant binding to plasma proteins, and
a low extraction fraction in brain with a limited
signal-to-background ratio [4, 5]. This led to the de-
velopment of second-generation TSPO radioligands
with lower non-specific binding and higher affinity
and specificity.
Preclinical data of the third-generation TSPO
radioligand [18F]GE-180 have demonstrated a higher
specific signal in affected brain regions and a lower
non-specific binding in healthy tissue than [11C](R)-
PK11195 in models of stroke [6] and neuroinflamma-
tion [7, 8]. Our own preclinical experience with this
tracer indicated a very good applicability for monitor-
ing neuroinflammatory disease as well [9]. First-in-
human studies with healthy controls (HC) found a
low first-pass extraction resulting in low uptake of
[18F]GE-180 in healthy tissue [10, 11]. Various
compartmental models with and without an extravas-
cular component that takes into account tracer bind-
ing to endothelial cells were investigated and the
authors suggested a two-tissue compartment model
without an extravascular component as the preferred
method for [18F]GE-180 quantification in healthy
controls and 90 min as the optimal scan length for
reliable estimation of volumes of distribution (VT)
[10, 11]. Distribution volumes from Logan plot and semi-
quantitative SUVs (60–90 min p.i.) correlated well with
VT from 2TC model [10, 11]. Although the so far available
pre-clinical data are promising, the performance of
[18F]GE-180 as a tracer for neuroinflammatory diseases in
human patients still needs to be verified.
This is the first study investigating relapsing-remitting
MS (RRMS) patients with [18F]GE-180 PET with the aim
of quantifying the uptake in various anatomical brain re-
gions and in focal lesions. In particular, we focused (1)
on the identification of a pseudo-reference region (PRR),
which is challenging in diseases with widespread inflam-
mation within the brain [12], and (2) on the comparison
of parameters obtained from dynamic and static data,
the latter one avoiding long scan times and demanding
data processing steps, with the goal of providing a
quantification procedure which is suitable for routine
clinical use.
Methods
Radiochemistry
As described previously [13], [18F]GE-180 production
was performed on a FASTLab synthesiser with single-
use disposable cassettes manufactured by GE Healthcare
(The Grove Centre Amersham, UK). Radiochemical purity
exceeded 95% and a high-specific activity was reached, ran-
ging between 2423 and 3293 GBq/μmol.
DNA extraction and polymorphism genotyping
Due to the reported dependency of binding properties of
the second-generation TSPO ligands on a genetic poly-
morphism of the TSPO gene, all individuals were geno-
typed and classified as low-, medium-, or high-affinity
binder (LAB, MAB, and HAB) [14–17]. Genotyping for
TSPO polymorphism was performed at the Department
of Psychiatry of the University Hospital Regensburg on
4 mL whole blood samples. Genomic DNA was ex-
tracted with QIAmp DNA blood maxi kit (Qiagen, Hil-
den, Germany) following the manufacturer’s protocol.
DNA quality assessment was performed with optical ab-
sorbance and gel electrophoresis. Exon 4 of the TSPO
gene containing the polymorphism rs6971 (Ala or Thr
at position 147) as well as exon/intron junctions were
PCR amplified and sequenced using Sanger method with
the primers ex4-F-AGTTGGGCAGTGGGACAG and
ex4-R-GCAGATCCTGCAGAGACGA. Sequencing data
were analysed using SnapGene software (GSL Biotech;
available at snapgene.com). The identified rs6971 geno-
types (C/C, C/T, or T/T) code for the amino acids Ala/
Ala, Ala/Thr, or Thr/Thr at position 147 of the TSPO
protein and were considered to generate a high-,
medium-, or low-affinity binding phenotype, respect-
ively [17].
Patient data and human subjects
Seventeen dynamic PET scans were performed in 14
RRMS patients (7 female and 7male; mean age 39 ± 9 years;
5 MAB and 9 HAB). At the time of the PET scan, 4 pa-
tients were without treatment, 5 patients were receiving
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rituximab, 3 patients were receiving glatirameracetate, 2
were receiving natalizumab, and 1 patient each was
treated with alemtuzumab, interferon-beta, and terifluno-
mide, respectively. The study with patients was approved
by the local ethics committee (IRB no. 601–16) and the
German radiation protection committee. All patients gave
written informed consent.
To determine the most affected brain regions and for
a reproducible definition of reference tissue in MS
patients, a database of 6 healthy controls (HC, 3 female
and 3 male; mean age 23 ± 6 years; 1 MAB and 5 HAB)
was provided by GE Healthcare (The Grove Centre
Amersham, UK). The underlying study of healthy sub-
jects was approved by the McMaster University Research
Ethics Board. Research was conducted in accordance
with the principles of the Declaration of Helsinki and all
subjects gave written informed consent.
Imaging
Dynamic HC PET studies (4 × 30, 3 × 60, 10 × 150,
12 × 300 s) were acquired after injection of 269 ± 7 MBq
[18F]GE-180 on a Biograph 6 PET/CT (Siemens Healthi-
neers, Erlangen, Germany) and reconstructed with
OSEM2D algorithm (8 iterations, 4 subsets, 4 mm Gauss).
Standard corrections for CT-based attenuation, scatter,
decay, and random counts were applied.
Seventeen dynamic PET studies of 14 RRMS patients were
performed on a Biograph 64 PET/CT device (Siemens
Healthineers, Erlangen, Germany). Based on previously pub-
lished experience with HC, a 90-min emission scan was ac-
quired in list mode, starting with injection of 189 ± 11 MBq
[18F]GE-180. Reconstruction with a 256 × 256 × 109 matrix,
voxel size of 1.336 × 1.336 × 2.027 mm3 (framing 12 × 10,
4 × 30, 2 × 60, 2 × 120, 16 × 300 s) was performed using
the same reconstruction settings as for HC data. PET data
were corrected for subject motion within the PMOD Fusion
tool (v3.5, PMOD Technologies, Zurich, Switzerland).
For each subject, a T1-weighted MRI scan with a slice
thickness of at least 3 mm was performed on a Magnetom
3T scanner (Siemens Healthineers, Erlangen, Germany)
with intravenous injection of 0.1 mmol/kg contrast agent
(Gd-BOPTA, MultiHance; Bracco Imaging, Milan, Italy).
Contrast-enhanced (CE) MRI images were co-registered
to the corresponding PET data.
Anatomical brain regions
For VOI-based analysis, anatomical brain regions were
defined with the workflow provided within the PMOD
Neuro tool (v3.5). First, each PET image was mapped to
the corresponding T1-weighted CE MRI image by rigid
matching using the default settings. Then, each MRI
image was normalised to the T1-weighted MRI template
in Montreal Neurological Institute (MNI) space. This
was followed by the application of a maximum
probability atlas (Hammers N30R83 [18]) for VOI defin-
ition. Grey matter was masked by application of the de-
fault threshold of 0.3 on the grey matter probability
atlas. Anatomical brain VOIs were then transformed
into PET space.
Reference tissue extraction
SUV was determined at 60 to 90 min p.i. (SUV60–90)
[11]. For the extraction of brain tissue which is least af-
fected by disease, a voxel-wise comparison of SUV60–90
(two sample t test) between HC and all MS patient scans
was conducted with statistical parametric mapping
(SPM8; Wellcome Trust Centre for Neuroimaging, UK)
assuming unequal variance. Smoothing of images was
not performed. For this purpose, PET data were mapped
into MNI space using the corresponding MRI images
with the PMOD Neuro tool as described in the previous
section. Anatomically defined brain volumes exhibiting a
low fraction of significant voxels in SPM were identified
by determination of the fraction of voxels with a t score
above 2.52 (P < 0.01) for each volume. Within these vol-
umes, the volume best suited for reduction of variability
of healthy tissue uptake was selected by calculating the
coefficients of variation of grey matter (GM) and white
matter (WM) uptake in HC after normalisation to each
eligible brain region.
This was followed by an exclusion of voxels sus-
pected of being affected by disease relying on mean
SUV60–90 and standard deviation (SD) from HC data
in this region. The optimal upper threshold
TPRR = mean + a × SD was iteratively adapted by
minimising the difference between the average PRR
time-activity curve (TAC) of RRMS patients and the
average FC TAC of HC.
Quantification with DVR and SUVR
Specific binding relative to non-displaceable uptake can
be derived directly from compartmental model parame-
ters (binding potential BPND = k3/k4). Alternatively, it
can be calculated from distribution volume ratios
(BPND = VT/VND − 1) [19]. Since there is no reference
tissue available for [18F]GE-180, which is devoid of specific
binding, the quantity of interest was specific binding rela-
tive to healthy tissue PRR (BP = VT/VPRR − 1 = DVR − 1),
which is smaller than BPND = DVR(1 + BPND,PRR) − 1
[20]. The Logan reference tissue model [21] was used to
determine DVR with PMOD Kinetic Modelling tool (v3.4)
from dynamic 20–90 min p.i. data [10]. The population
average rate k2’
REF of the reference tissue was set to 0.027
1/min according to the previously published average value
for frontal cortex k2 estimated with one-tissue compart-
ment model [11]. For one exemplary patient, a parametric
DVR map was generated from dynamic data recon-
structed with a 10-mm Gauss filter. Due to high statistical
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fluctuations, the coarse filter had to be applied for voxel-
wise fitting with Logan reference tissue model.
To assess whether modelling based on dynamic 20–
90 min p.i. data can be replaced by values obtained from
shorter static scans, a simple quantification based on
standardised uptake value ratios (SUVR = SUV60–90/
SUVPRR,60–90) was carried out by comparison with DVR
obtained from Logan reference tissue model. Correlation
was determined for all brain tissue regions and lesions.
Segmentation of MS lesions
VOIs of 67 focal MS lesions visible in PET were defined
on SUVR images. A delineation method, which aims to
find the boundary reproducing threshold TSUVR based
on the mean signal from 32 hottest voxels of each lesion
(SUVR32Vox, total volume of 0.116 mL) and affected
white matter background (BG) value, was applied [22]:
TSUVR ¼ SUVR32Vox−SUVRBGð Þ  Fþ SUVRBG ð1Þ
The fraction F = 0.35 was derived from a Nema-NU2-
2001 phantom measurement consisting of six hot spheres
in BG (1:8) with different volumes (0.5–26.5 mL). The
affected WM uptake normalised to PRR averaged over all
patients served as BG for the delineation of locally elevated
uptake within WM without being influenced by a patient-
specific lesion load. Alternatively, background volumes sur-
rounding the focal lesions can be delineated manually for
each patient.
Statistical analysis
Results are presented as mean ± SD. Analysis of group-
wise differences between different binding affinity groups
and VOI parameters of HC and MS patient data was cal-
culated with Mann-Whitney U test (U test) using
MATLAB (MathWorks, USA), where P < 0.05 was
considered as a significant difference. Linear correlation
of quantitative parameters was performed (Pearson,
MATLAB, MathWorks, USA).
Results
[18F]GE-180 uptake in MS patients
TAC averaged over all RRMS patient scans are shown in
Fig. 1a. [18F]GE-180 uptake in brain tissue peaked at
about 35 s p.i. with the lowest mean peak-SUV in white
matter (0.88 ± 0.3) and the highest mean peak SUV in
the thalamus (1.24 ± 0.4) and brainstem (1.16 ± 0.4).
Mean peak SUV in cortical and cerebellar grey matter
was similar (1.06 ± 0.4, 1.13 ± 0.4). While cortical and
cerebellar GM reached a plateau after about 60 min p.i,
the brainstem, WM, and also the thalamus of the MS
patients exhibited a slowly increasing TAC after the fast
wash-out. SUV60–90 was lowest in white matter
(0.41 ± 0.05), and highest in brainstem (0.49 ± 0.06) and
thalamus (0.48 ± 0.05). SUV60–90 in cortical GM was
0.43 ± 0.05 and in cerebellar GM 0.44 ± 0.06. In contrast
to the uptake kinetics of apparently not affected tissue,
MS lesions exhibited a constant increase or saturation of
uptake (Fig. 1b) with a mean SUV60–90 of 0.7 ± 0.2.
No significant differences (U test P > 0.05) in SUV60–90
were found between MAB and HAB in all anatomical
brain regions (e.g. combined frontal, temporal, and par-
ietal cortex SUV: MAB = 0.41 ± 0.04, HAB = 0.41 ± 0.05).
Reference tissue extraction
Results from SPM group analysis on static 60 to 90 min
p.i. images are given in Fig. 2. The t score images are
given for a cut-off threshold of P < 0.01. White matter
(average t score 2.7 and P = 0.03) and the thalamus
(average t score 2.6 and P = 0.06) exhibited the highest
fraction of voxels with P < 0.01 (> 55%). The fraction
with P < 0.01 was below 25% in the frontal lobe,
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Fig. 1 [18F]GE-180 time-activity curves in SUV averaged over all MS patient studies. a Mean TAC of brainstem (circle), cortical GM (square), thalamus
(cross), cerebellar GM (diamond), and white matter (triangle). b Mean ± SD TAC averaged over 67 lesions
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temporal lobe, and in cerebellar grey matter (average t
score < 1.8 and P > 0.10). Normalisation to frontal cortex
(FC) led to the lowest variability of grey and white mat-
ter uptake (GM decreased from 12 to 6%, WM remained
at 7%) in HC. Therefore, FC was chosen as the anatom-
ically defined primary reference tissue.
Mean frontal cortex SUV60–90 in HC was 0.37 ± 0.04.
The optimal upper threshold for unaffected FC voxels
obtained by iterative adoption was:
TPRR ¼ meanHC þ 1:7 SDHC ð2Þ
This corresponds to a SUV60–90 threshold of 0.433.
The resulting corrected FC volume applied in the follow-
ing as pseudo-reference region yielded a SUV60–90 of
0.37 ± 0.03 averaged over all MS patient studies. No sig-
nificant difference was found between the corrected
frontal cortex SUV60–90 in MS patients and the corre-
sponding values in HC (Fig. 3, U test P = 0.42). Based
on this pseudo-reference region, SUVR images were
generated as visualised in Fig. 4. Variability in uptake
values in patients reduced with PRR normalisation for
GM from 11 to 7%, and for WM from 13 to 10%.
Quantification with DVR and SUVR
The linear part of the Logan plot started earlier for brain
tissue data than for lesion data and both reached linear-
ity (Fig. 5). DVR derived from Logan reference tissue
model showed a very strong correlation with SUVR
(Fig. 6: anatomical brain regions ρ = 0.97, P < 0.001, and
lesions ρ = 0.93, P < 0.001). In RRMS patients, thalamus
and brainstem exhibited the highest values (SUVR
1.33 ± 0.11 and 1.35 ± 0.17, DVR 1.35 ± 0.14 and
1.45 ± 0.24) and WM and cortical GM the lowest (SUVR
1.11 ± 0.11 and 1.16 ± 0.09, DVR 1.19 ± 0.13 and
1.18 ± 0.10).
For observer-independent assessment of inflammation
activity in focal lesions, a SUVR of 1.3 was assumed as
affected WM background. This value was derived from
SUVR images normalised to PRR by adoption of Eq. (2):
TLesion,BG = meanHC,WM + 1.7 × SDHC, where TLesion,BG
served as lower threshold for the definition of affected
white matter voxels in MS patients. For all RRMS pa-
tients studied, the average SUVR of lesions delineated by
this method was between 1.3 and 3.2 (mean 1.9 ± 0.5).
Maximum SUVR within lesions ranged between 1.5 and
4.9 (2.4 ± 0.9). All MS lesions exhibited an increasing or
saturating TAC (Fig. 1b).
Discussion
This study aimed to provide a robust, clinically suitable
quantification approach for the third-generation TSPO
ligand [18F]GE-180 in MS patients. The investigated
static 60–90 min imaging containing a PRR-based SUVR
quantification correlated well with DVR from modelling
by application of the Logan reference tissue model on
dynamic 90 min and thus proved suitability for clinical
TSPO PET application, when patient compliance and
economic aspects have to be considered. The presence of
non-saturated lesion TACs suggests that a prolongation of
the scan duration, at the cost of a lower count statistic,
might allow for an improved assessment of equilibrium
and tracer wash-out.
Fig. 2 Statistical parametric maps from two sample t test with an extent threshold of 60 voxels with t score values showing differences in [18F]GE-180
uptake in static 60 to 90 min p.i. images between healthy controls and all MS patient scans with a cut-off threshold of P < 0.01 in triangular views
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Fig. 3 Time-activity curves of frontal cortex in healthy controls
(cross), and original frontal cortex (square) and pseudo-reference
region (triangle) averaged over all MS patient scans
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Binding potentials derived with reference modelling
(BP = DVR − 1) reported previously for the prototypic
TSPO ligand [11C](R)-PK11195 in healthy controls, and
MS patients were in a similar range as results presented
here for [18F]GE-180: the lowest BP was found in
normal-appearing white matter and the highest BP in
the thalamus and the brainstem [23–25]. In agreement
with our SPM analysis results, PET signal was signifi-
cantly elevated compared to HC in contrast-enhancing
lesions, thalamus, parts of the brainstem, and in white
matter frequently following white matter fibre tracts
[23, 25–27].
MS lesions exhibited a high [18F]GE-180 uptake and
contrast, enabling a visual detection of focally elevated
tracer accumulations (Fig. 4). The lesion-to-WM-back-
ground ratio (up to a threefold increase in mean lesion
SUVR) appears to be high for [18F]GE-180 compared to
other TSPO radioligands previously used in MS patients
[23–30]. [11C]PK11195 signal in static images normal-
ised to cortical grey matter was significantly higher in
lesions with CE in MRI compared to normal white mat-
ter (up to a factor of 1.4) [26]. For [18F]FEDAA1106,
lesions with CE in MRI were not detectable in SUV and
Logan VT images, probably due to a high non-specific
uptake [30]. Both [18F]PBR111 and [11C]PBR28 showed
an increased VT in some lesions with CE in MRI [24, 28,
29]. However, for [11C]PBR28, static SUV90–120 images
were too noisy for visual detection of MS lesions, most
probably due to the short half-life of 11C in combination
with a high-resolution PET tomograph [29].
The critical aspect for robust and reliable lesion quanti-
fication is the choice of the reference region. It is difficult
to propose a standard reference region for all neurological
diseases since patterns of affection vary widely. In MS, im-
mune cell infiltration is predominantly localised in focal
white matter lesions. However, as the disease progresses,
inflammatory changes spread throughout the CNS and no
region can be assumed to be unaffected. The corrected
frontal cortex seems to be a suitable pseudo-reference
region, at least for RRMS patients, since grey matter was
reported to be less affected than white matter in early
stages of MS [24–26, 28]. In order to identify the least af-
fected regions in RRMS patients, we compared our
patients with a group of young HC, in which no CNS in-
flammation should be present. Although the SPM analysis
revealed a non-negligible fraction (24%) affected by dis-
ease in the frontal cortex, time activity curves were not
significantly different for HC and RRMS patients in this
Fig. 4 Images of an MS patient in native [18F]GE-180 PET space. Top row: T1-weighted contrast-enhanced MRI. Second row: SUV image (60–90 min
p.i.). Third and bottom row: DVR (from dynamic data reconstructed with 10-mm Gauss filter) and SUVR with lower threshold set to 1.0 for the depiction
of specific binding relative to the PRR. a Whole head in triangular views. b Application of brain mask onto parametric maps for two different transaxial
planes with MRI overlay
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region, and it was feasible to exclude suspicious voxels in
this relatively large and well-defined region. The VOI-
based comparison of PRR SUVs with HC data showed
good concordance. Normalisation of PET data by the cor-
rected frontal cortex uptake reduced inter-patient variabil-
ity in grey (from 11 to 7%) and white matter (from 13 to
10%) signals.
Alternative methods recommended for reference tissue
TAC generation of TSPO tracers are data-driven cluster-
ing (DC) [31, 32] or supervised clustering (SC) on dy-
namic data preselected with a brain mask [33, 34]. SC
has been validated for [11C](R)-PK11195 and also tested
for [18F]GE-180 [8]. However, DC and SC require dy-
namic PET studies and previous publications show that
SC might not sufficiently exclude affected voxels in some
cases and that other methods might be superior for the
exclusion of affected voxels [8, 35]. A promising
approach using fixed thresholds for the definition of af-
fected voxels was applied to BP images derived with SC
reference tissue [23] but also needs dynamic imaging.
The reported high inter- and intra-subject variability
found for second-generation radioligands in other stud-
ies was attributed to differences in binding affinity status
and in plasma protein binding [5, 36, 37]. For [11C](R)-
PK11195, in vitro and in vivo data show no significant
differences between binding affinity groups. Unpublished
in vitro work by D. Owen with cold GE-180 displacing
[3H]PK11195 has shown a binding affinity ratio of 15:1
between HABs and MABs [11]. However, Feeney et al.
[11] found no significant differences between MABs and
HABs similar to [11C](R)-PK11195 in healthy brain tis-
sue of human subjects [16]. This is in line with the re-
sults of our current study in which we found no
differences between MAB and HAB. Although in vitro
prediction of differences in specific binding can differ
from the relation observed for in vivo data [15, 38], it is
questionable whether this can explain the results. Such a
discrepancy may be explained by the high dependency of
the in vitro studies on experimental conditions like
temperature, fluid composition, and presence of intact
mitochondria [15]. Furthermore, brain microvascular
endothelial cells change BBB properties in vitro [39]. Fan
et al. [10] suggest that the finding that no differences
could be observed in vivo may be caused by a lower
TSPO affinity of [18F]GE-180 compared to other
second-generation TSPO tracers. Another explanation
proposed by both previous studies is the low brain tissue
uptake [10, 11]. The high fraction of ligand bound to
plasma proteins, probably resulting from a relatively
high lipophilicity (logD at pH 7.4 is 2.95 [40]), may be
the reason for the slow propagation into tissue and the
constantly high activity concentration in blood vessels
dominating signal in healthy tissue (suggesting similar-
ities to [11C](R)-PK11195 in vivo) [41, 42]. Another rea-
son for low uptake in brain may be a fast clearance by
efflux pumps.
Yet, we observe a high contrast in MS lesions and also
in gliomas as published recently [43]. The important
question is what are the underlying processes leading to
this contrast. Does it reflect specific binding to TSPO or
rather other processes like a BBB breakdown? For gli-
omas, we could demonstrate that [18F]GE-180 uptake
patterns do not correlate with contrast enhancement in
T1-weighted MRI images and that even for some gli-
omas, the highest [18F]GE-180 uptake can be found in
non-contrast-enhancing tumour areas [43]. Still one
might hypothesise that those areas exhibit micro BBB
breakdown without apparent enhancement of contrast
agent in MRI [44], which may allow the passage of
[18F]GE-180 through the leaky BBB. However, we also
observe areas with CE in T1-weighted MRI, i.e. with
BBB breakdown, but without elevated [18F]GE-180
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uptake [43]. Even if micro BBB breakdown might ease
the supply of [18F]GE-180, the [18F]GE-180 signal inten-
sity does not correlate with severity of BBB breakdown,
leading to the assumption that the dominant process
resulting in the observed high range of [18F]GE-180
binding should be attributed to TSPO expression levels
rather than mere BBB breakdown. Nevertheless, the lack
of micro BBB breakdown in some regions may lead to
an underestimation of TSPO expression.
One limitation of this study may be the usage of data
from two different PET/CT devices in which the PET
part is identical, but the CT data may yield a slightly dif-
ferent attenuation correction. Also, for future clinical
studies, it would be beneficial to gather a larger database
of HC with varying age to account for age-related changes.
Furthermore, for an encompassing and comprehensive in-
terpretation of the underlying processes, it is indispensable
to perform in vivo blocking studies in combination with
pharmacokinetic modelling with a metabolite corrected
arterial input function and a longer scan duration.
The possibility of static PET imaging provided by the
proposed method in contrast to dynamic PET imaging
will greatly increase the acceptance by patients, as 30-
min scans are usually well-tolerated and the imaging
protocol does not include blood sampling, which is often
perceived as an invasive, displeasing method by patients
and is therefore often avoided in clinical settings. With
these tools, TSPO PET with [18F]GE-180 may enable
straightforward clinical assessment of neuroinflamma-
tory activity in MS beyond the scope of structural MRI
and seems to be a highly promising imaging method
to assess disease activity and therapy response in
RRMS patients.
Conclusions
In patients suffering from RRMS, the new TSPO ligand
[18F]GE-180 presented a highly elevated signal up to a
threefold increase in SUVR of focal lesions compared to
surrounding background. Our data demonstrate a high
correlation between parameters obtained from dynamic
PET imaging with simple SUV ratios extracted from static
60–90 min [18F]GE-180 PET scans using the corrected
frontal cortex as pseudo-reference region.
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Voxel-wise analysis of dynamic 18F-FET PET:
a novel approach for non-invasive glioma
characterisation
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Abstract
Background: Glioma grading with dynamic 18F-FET PET (0–40 min p.i.) is typically performed by analysing the
mean time-activity curve of the entire tumour or a suspicious area within a heterogeneous tumour. This work
aimed to ensure a reader-independent glioma characterisation and identification of aggressive sub-volumes by
performing a voxel-based analysis with diagnostically relevant kinetic and static 18F-FET PET parameters.
One hundred sixty-two patients with a newly diagnosed glioma classified according to histologic and molecular
genetic properties were evaluated. The biological tumour volume (BTV) was segmented in static 20–40 min p.i. 18F-FET
PET images using the established threshold of 1.6 × background activity. For each enclosed voxel, the time-to-peak
(TTP), the late slope (Slope15–40), and the tumour-to-background ratios (TBR5–15, TBR20–40) obtained from 5 to 15 min p.i.
and 20 to 40 min p.i. images were determined. The percentage portion of these values within the BTV was evaluated
with percentage volume fractions (PVFs) and cumulated percentage volume histograms (PVHs). The ability
to differentiate histologic and molecular genetic classes was assessed and compared to volume-of-interest (VOI)-based
parameters.
Results: Aggressive WHO grades III and IV and IDH-wildtype gliomas were dominated by a high proportion of voxels
with an early peak, negative slope, and high TBR, whereby the PVHs with TTP < 20 min p.i., Slope15–40 < 0 SUV/h, and
TBR5–15 and TBR20–40 > 2 yielded the most significant differences between glioma grades. We found significant differences
of the parameters between WHO grades and IDH mutation status, where the effect size was predominantly higher for
voxel-based PVHs compared to the corresponding VOI-based parameters. A low overlap of BTV sub-volumes defined by
TTP < 20 min p.i. and negative Slope15–40 with TBR5–15 > 2- and TBR20–40 > 2-defined hotspots was observed.
Conclusions: The presented approach applying voxel-wise analysis of dynamic 18F-FET PET enables an enhanced
characterisation of gliomas and might potentially provide a fast identification of aggressive sub-volumes within the BTV.
Parametric 3D 18F-FET PET information as investigated in this study has the potential to guide individual therapy
instrumentation and may be included in future biopsy studies.
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Background
Structural imaging with T1-weighted magnetic resonance
imaging (MRI) [1], which is the gold standard in clinical
glioma assessment, is restricted to the interpretation of
properties like tumour contour, localisation, and enhance-
ment pattern [1]. Besides, several functional MRI tech-
niques have shown relevance for prediction of malignant
transformation, involving, e.g. perfusion-weighted imaging
(PWI) yielding information on relative cerebral blood vol-
ume and flow (rCBV, rCBF) [2–4]. In contrast, positron
emission tomography (PET) with amino acids aims to dir-
ectly image an elevated amino acid metabolism of rapidly
proliferating tumour cells [5–7]. According to the report
on response assessment in neuro-oncology (RANO), dy-
namic O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET has
shown its usefulness in diagnosis, in prognosis of tumour
progression, and in assessment of treatment response [8].
The current standard procedure for retrieving infor-
mation from dynamic 18F-FET PET consists of evaluat-
ing parameters such as the tumour-to-background ratio
(TBR) at a certain time point, the late slope, the time-ac-
tivity curve (TAC) pattern, and the time-to-peak (TTP)
[9–16]. In particular, the TTP and the TAC pattern have
proven to be suitable for identification of tumour recur-
rence or progression [12, 13, 17], and for glioma grading
[14, 15, 18]. Pharmacokinetic modelling of 18F-FET up-
take has also been considered. However, to our know-
ledge, its clinical relevance could not be shown yet, and
the requirement of (metabolite-corrected) plasma-in-
put data impairs the clinical applicability [19, 20].
While a slowly increasing TAC is characteristic of
low-grade gliomas, the TAC of high-grade gliomas
tends to exhibit a short TTP and decreasing TAC
[17, 21]. Those parameters are most frequently de-
rived from a mean volume-of-interest (VOI)-TAC of
the entire tumour or from the hot-spot of the tumour
with a 90% isocontour [17, 22]. However, in case of
heterogeneous tumours, it may occur that the
hot-spot in summation images does not correspond
to the tumour fraction defined as most suspicious re-
garding tumour aggressiveness according to TTP and
TAC pattern. This may potentially lead to an under-
estimation of malignancy and might impair treatment
planning. Recent approaches in current research aim-
ing to improve the assessment of tumour characteristics
include, e.g. a slice-by-slice TAC analysis or the extraction of
texture parameters from static 18F-FET PET images [23, 24].
The goal of this study was to investigate the
intra-tumoural distribution of the abovementioned
diagnostically relevant kinetic and static parameters
derived from dynamic 18F-FET PET data on a voxel
basis. A comparison with VOI-based methods, as cur-
rently utilised for non-invasive glioma characterisation
in clinical routine, is provided.
Methods
Patients
For this retrospective study we included 162 18F-FET
PET positive patients with a newly diagnosed, untreated
glioma who had undergone a dynamic 40 min 18F-FET
PET scan prior to diagnosis according to either biopsy
or resection. Both stereotactic biopsy and tumour resec-
tion were performed using navigation software (Brainlab
iPlan version 3.0, Brainlab, Feldkirchen, Germany). The
choice of surgical procedure was based on tumour loca-
tion, patient age, and performance status as well as pa-
tient preference; all treatment decisions have been
approved by an interdisciplinary tumour board. Neuro-
pathological diagnosis and grading have been performed
by at least two neuropathologists as part of the clinical
routine as described previously [18, 25]. Besides hist-
ology, mutation of IDH1/2 gene and, in case of IDH1
mutation, co-deletion of chromosomal material on 1p/
19q were analysed in accordance with the recently re-
vised version of the WHO grading system for central
nervous tumours [26]. The study was approved by the
local ethical review board and all patients gave written
informed consent (IRB 606-16).
Imaging
Dynamic 18F-FET PET scans were acquired on an ECAT
EXACT HR+ scanner (Siemens Healthineers, Erlangen,
Germany) after intravenous bolus injection of 176 ±
13 MBq 18F-FET, according to the protocol described in
[9, 11]. For patient comfort and minimization of motion
during the scan, patients were carefully positioned and
fixed. Dynamic 40-min emission data were recorded in 3D
mode with 16 frames (7 × 10 s, 3 × 30 s, 1 × 2 min, 3 ×
5 min, and 2 × 10 min). Standard corrections for random
and scattered coincidences, dead time, decay, and attenu-
ation were performed. Attenuation correction was based
on transmission scans measured with three rotating 68Ge
line sources. Data were reconstructed with filtered
back-projection and a 4.9-mm Hann filter. Matrix size
was 128 × 128 × 63, and voxel size 2.03 × 2.03 × 2.43 mm3.
All dynamic PET scans were checked frame-by-frame for
head movement. Motion correction was performed on af-
fected time frames within PMOD Fusion tool (v3.5,
PMOD Technologies, Zurich, Switzerland).
Delineation of tumour volume
Biological tumour volume (BTV) was defined by a
TBR20–40 above 1.6 in static 20–40 min p.i. summation
images [15, 27]. Background (BG) values were derived
from a crescent-shaped volume of interest (VOI) as de-
scribed previously [28]. VOIs were defined within the
PMOD View tool (version 3.5, PMOD Technologies,
Zurich, Switzerland). Only tumour volumes consisting
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of more than 18 voxels were included, approximating
the volumetric PET image resolution.
Extraction of ‘percentage volume fractions’ and
‘percentage volume histograms’
Voxel-wise analysis was performed with an in-house de-
veloped software (C++ with integration of the ROOT
data analysis framework, version 6.09/01, Cern,
Switzerland; and ITK segmentation and registration tool-
kit, version 4.11, National Library of Medicine). For each
voxel within the BTV, the following kinetic and static pa-
rameters were determined: the TTP, the late slope
(Slope15–40, 15–40 min p.i.), and the tumour-to-back-
ground ratios TBR5–15 and TBR20–40 in early 5–15 min
p.i. and late 20–40 min p.i. summation images, with the
BG signal derived from the respective time frame. The
Slope15–40 was estimated by linear fitting of the last three
time points, and the TTP was estimated as the time cor-
responding to the maximal TAC value starting from
2.7 min p.i. to avoid influence from early blood signal.
Within the BTV, the sub-volume fractions consisting of
voxels with a specific parameter value were determined
and stored in histograms. For this, the histograms were
plotted with the binned parameter values on the x-axis
(histogram bin sizes: time frames of dynamic PET images
for TTP, 0.6 SUV/h for Slope15–40, and 0.25 for TBR) and
the percentage fractions of the total BTV on the y-axis
(percentage volume fractions, PVFs). Cumulated percent-
age volume histograms (PVHs) were obtained by cumu-
lating these PVF histograms up to the specific bin, to
improve the robustness of parameter effect quantification
[29, 30]. For example PVFTTP15–20 corresponds to the
percentage portion of voxels within the BTV with peak
value in time frame 14 (15–20 min p.i.), and PVHTTP < 20
to the cumulated percentage portion of voxels with TTP
< 20 min p.i.. In order to exemplarily illustrate the influ-
ence of noise in dynamic PET data onto the estimation of
parametric TTP and Slope15–40 images, a simple method
for noise reduction, a spatial Gaussian filter with 10 mm
full width half maximum (FWHM), was applied to the
dynamic PET data prior to the estimation and analysis of
alternative TTP and Slope15–40 images.
Extraction of VOI-based parameters
For comparison, the following parameters were assessed:
TBR5–15,mean and TBR20–40,mean from a mean VOI-TAC
(TBR20–40 > 1.6) and the maximal TBR5–15,max and
TBR20–40,max. The VOI for dynamic analysis with TTP
and late Slope15–40 was obtained with an isocontour set
to 90% of maximum uptake in 10–30 min p.i. summa-
tion images, yielding a mean TAC characterising the
tumour hot-spot [17, 22].
Statistical analysis
Results are presented as mean value and standard devi-
ation. Statistical analysis was performed with IBM SPSS
Statistics (version 24, IBM Corp., Armonk, NY, USA).
The threshold for sub-volume fractions defined in the
PVH of each derived parameter was optimised by evalu-
ating the overall group differences using the Kruskal-
Wallis H test. Differences between three groups (mo-
lecular genetic sub-groups or WHO grades) were
assessed with the Kruskal-Wallis H test (effect size, r
= √(H2/(N − 1), where H is the test statistic and N the
sample size)). This was followed by Dunn-Bonferroni
post-hoc analysis for the extraction of significant differ-
ences between two groups (effect size, r = |Z|/√N, where
Z is the Z score and N the sample size). Receiver-operat-
ing characteristics (ROC) analysis was performed in
order to determine the cut-off values for distinguishing
IDH-wt from IDH-mut gliomas and WHO grade III/ IV
from WHO grade II gliomas. For each test, the threshold
(T) yielding the highest product of sensitivity (Se) and
specificity (Sp) was chosen as optimal cut-off value.
Additionally, H test and post hoc analysis were per-
formed for sub-groups separated according to both mo-
lecular genetic and histologic features. Differences
between WHO grades II and III of IDH-mut codel gli-
omas (i.e. no WHO grade IV) were assessed with Mann-
Whitney U test.
The similarity between two sub-volume fractions was
quantified with the Sørensen-Dice coefficient, i.e. two
times the intersection volume divided by the sum of both
volumes (2 × (volume1 ∩ volume2)/(volume1 + volume2)).
Statistical significance was defined as two-tailed p value
below 0.05.
Results
Patients
One hundred twelve patients had a biopsy, and 40 pa-
tients underwent a microsurgical tumour resection. In
sum, 39 IDH1/2-mutant and 1p/19q-codeleted oligo-
dendrogliomas (IDH-mut codel), 39 IDH1/2-mutant as-
trocytomas (IDH-mut non-codel), 39 IDH1/2-wildtype
astrocytomas (IDH-wt), 6 IDH1/2-mutant glioblastomas
(GBM IDH-mut), and 39 IDH1/2-wildtype glioblastomas
(GBM IDH-wt) were included. Histologic evaluation re-
vealed 55 WHO grade II gliomas, 62 WHO grade III gli-
omas, and 45 WHO grade IV gliomas. The patient
characteristics are given in Table 1.
Statistical analysis
The VOI-based parameters and voxel-based PVHs are
presented with respect to WHO grade differentiation
(Table 2), molecular genetic differentiation (Table 3),
and a combination of both (Table 4). All tables show
mean and standard deviation of the parameters.
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Significance of differences in parameters was predomin-
antly higher for PVH data compared to VOI-based pa-
rameters especially in case of molecular genetic
differentiation and for differences between WHO grade
II and WHO grade III/ IV gliomas. In the following, the
respective results for (1) VOI-based and (2) voxel-based
analyses are presented. Mean values and results from
Kruskal-Wallis H test are presented in Tables 2, 3, and 4
with post hoc results coded with upperscript signs (a
complete list of results is given in Additional file 1: Table
S1, results from ROC analysis are illustrated in Add-
itional file 1: Table S2).
VOI-based parameters
Figure 1 shows the mean TACs of tumour hotspots
(90% isocontour) which were used for dynamic analysis
separated according to molecular genetic and histologic
features. The mean and standard deviation of the param-
eters are given in the upper parts of Tables 2, 3, and 4.
All considered VOI-based parameters yielded significant
differences (p < 0.001) between WHO grades (Table 2),
with the highest effect size for TBR5–15,mean (r = 0.53).
TBR20–40,max was not able to differentiate between WHO
grade II and III gliomas (P = 0.053, r = 0.19), and the effect
size for TBR20–40,mean was low (P = 0.023, r = 0.21). The
highest effect size for distinguishing WHO grade III from
II was found for the TTP (P < 0.001, r = 0.30, AUC = 0.70,
for T = 21 min p.i.: Se = 69%, Sp = 67%), and TBR5–15,mean
(P < 0.001, r = 0.37, AUC = 0.76, for T = 1.9: Se = 77%, Sp
= 67%). The differences between WHO grades II and IV
were strongly significant for all parameters (P < 0.001)
with highest effect size for TBR5–15,max (r = 0.49, AUC =
0.86, for T = 3.4: Se = 91%, Sp = 78%) and TBR5–15,mean (r
= 0.51, AUC= 0.87 for T = 2.1: Se = 84%, Sp = 80%). TTP,
Slope15–40, and TBR5–15,mean were not able to differentiate
between WHO grades III and IV (P = 0.957, r = 0.08; P =
0.554, r = 0.10; P = 0.091, r = 0.17), and the most signifi-
cant differences were found for TBR20–40,max (P = 0.002, r
= 0.27, AUC = 0.69, for T = 3.0: Se = 80%, Sp = 56%).
Table 1 Patient characteristics
Patients 162
Gender (f; m) 67; 95
Age (year) 49 ± 15
Procedure for diagnosis
Biopsy 122
Surgery 40
WHO grade
II 55
III 62
IV 45
Molecular genetic and histologic classification
IDH-mut, non-codel (WHO II; III) 39 (19; 20)
IDH-mut, codel (WHO II; III) 39 (24; 15)
IDH-wt (WHO II; III) 39 (12; 27)
GBM IDH-mut 6
GBM IDH-wt 39
Table 2 TTP (units: min p.i.), Slope15–40 (units: SUV/h), TBR (units: 1), and BTV20–40 (units: mL) from VOI-based analysis and voxel-wise
PVH (units: %) separated according to histologic grading
Tumour VOI, post-filtering Parameter WHO II (55) WHO III (62) WHO IV (45) H test P; r Post hoc
90% isocontour TTP 25 ± 8 19 ± 9 17 ± 8 < 0.001; 0.39 *°
Slope15–40 − 0.0 ± 0.9 − 0.9 ± 1.6 − 1.0 ± 1.2 < 0.001; 0.36 *°
TBR20–40 > 1.6 TBR5–15,max 2.9 ± 1.1 3.9 ± 1.6 4.6 ± 1.2 < 0.001; 0.50 *°
#
TBR5–15,mean 1.8 ± 0.3 2.2 ± 0.5 2.4 ± 0.4 < 0.001; 0.53 *°
TBR20–40,max 2.8 ± 0.9 3.4 ± 1.3 4.0 ± 1.0 < 0.001; 0.43 °
#
TBR20–40,mean 1.9 ± 0.2 2.1 ± 0.4 2.2 ± 0.3 < 0.001; 0.43 *°
#
BTV20–40 15 ± 16 26 ± 30 36 ± 25 < 0.001; 0.38 °
#
PVHTBR,5–15 > 2 25 ± 24 53 ± 27 64 ± 18 < 0.001; 0.55 *°
PVHTBR,20–40 > 2 26 ± 21 37 ± 24 51 ± 17 < 0.001; 0.43 *°
#
PVHTTP > 30 50 ± 23 32 ± 23 25 ± 15 < 0.001; 0.43 *°
PVHTTP < 15 11 ± 14 26 ± 25 31 ± 15 < 0.001; 0.47 *°
PVHTTP < 20 23 ± 20 45 ± 29 52 ± 18 < 0.001; 0.49 *°
PVHSlope < 0 25 ± 19 46 ± 27 50 ± 17 < 0.001; 0.47 *°
TBR20–40 > 1.6, 10 mm Gauss PVHGaussTTP > 30 67 ± 28 41 ± 34 32 ± 23 < 0.001; 0.44 *°
PVHGauss TTP < 20 13 ± 20 39 ± 34 44 ± 24 < 0.001; 0.51 *°
PVHGauss,Slope < 0 16 ± 23 45 ± 36 51 ± 26 < 0.001; 0.50 *°
Post hoc P < 0.05: WHO grade * II vs. III, ° II vs. IV, # III vs. IV
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Molecular genetic differentiation (Table 3) was
strongly significant (P < 0.001) for TTP (r = 0.45),
Slope15–40 (r = 0.44), TBR5–15,max (r = 0.37), and TBR5–
15,mean (r = 0.45). Differences in TBR20–40,max and in
TBR20–40,mean were not significant (P = 0.056, r = 0.19; P
= 0.075, r = 0.18). None of the parameters differentiated
IDH-mut non-codel and codel gliomas (P > 0.846, r <
0.08). Differences between IDH-mut non-codel or IDH--
mut codel and IDH-wt gliomas exhibited the highest ef-
fect size (with P < 0.001) for Slope15–40 (r = 0.38, AUC =
0.75, for T = − 0.4 SUV/h: Se = 74%, Sp = 69%; r = 0.34,
AUC = 0.75, for T = − 0.4 SUV/h: Se = 73%. Sp = 74%)
and TBR5–15,mean (r = 0.39, AUC = 0.77, for T = 2.1: Se =
78%, Sp = 71%; r = 0.35, AUC = 0.76, for T = 2.1: Se =
78%, Sp = 79%).
Percentage volume fractions and percentage volume
histograms
Data from voxel-wise analysis of TTP, Slope15–40, and
TBR5–15 are presented in Figs. 2, 3, and 4. The upper
rows depict PVFs, and the middle rows the correspond-
ing cumulated PVFs as PVHs. The red lines represent
the PVH cut-offs optimised to yield most significant dif-
ferences between all glioma entities (minimal P value
with Kruskal-Wallis H test). This resulted in the defin-
ition of volume fractions considered to be suspicious of
aggressive high-grade characteristics: voxels with TTP
below 20 min p.i. (PVHTTP < 20), negative Slope15–40
(PVHSlope < 0), TBR5–15 above 2 (PVHTBR,5–15 > 2), and
TBR20–40 above 2 (PVHTBR,20–40 > 2) (Tables 2, 3, and 4
and lower rows of Figs. 2, 3, and 4). Additionally, the
PVH values for TTP above 30 min p.i. and below
15 min p.i. were included (PVHTTP > 30, PVHTTP < 15).
All PVH-based parameters showed strongly significant
differences between the WHO grades (P < 0.001), with the
highest effect size for PVHTBR,5–15 > 2 (r = 0.55) (Table 2).
The differentiation of WHO grades II and III and WHO
grades II and IV remained strongly significant (P < 0.001)
for all PVH-based parameters except for PVHTBR,20–40 > 2
(WHO grade II vs. III: P = 0.022, r = 0.21). Effect size was
again the highest for PVHTBR,5–15 > 2 (distinguish WHO
grade III from II: r = 0.40, AUC = 0.77, for T = 39%: Se =
73%, Sp = 75%; WHO grade IV from II: r = 0.53, AUC =
0.89, for T = 39%: Se = 91%, Sp = 75%). In contrast, differ-
entiation of WHO grade IV from III was only significant
for PVHTBR,20–40 > 2 (P = 0.007, r = 0.24, AUC = 0.66, for T
= 44%, Se = 69%, Sp = 61%).
All PVH data except PVHTBR,20–40 > 2 (P = 0.072, r =
0.18) yielded strongly significant (P < 0.001) differences
between molecular genetic groups and remained
strongly significant in post hoc analysis of differences be-
tween IDH-mut (non-codel; codel) and IDH-wt gliomas.
The highest effect size in post hoc analysis was found
for PVHTTP < 20 (r = 0.47, AUC = 0.82, for T = 38%: Se =
77%, Sp = 76%; r = 0.47, AUC = 0.86, for T = 41%: Se =
74%, Sp = 90%) and PVHSlope < 0 (r = 0.47, AUC = 0.81,
for T = 31%: Se = 86%, Sp = 71%; r = 0.48, AUC = 0.86,
for T = 40%: Se = 77%, Sp = 90%).
For a more precise interpretation of the results, glioma
types were also separated according to both molecular
genetic and histologic features (Table 4). As expected,
the mean fraction with early peak (PVHTTP < 20) and
Table 3 Data shown as in Table 2, separated according to molecular genetic grading
Tumour VOI, post-filtering Parameter IDH-mut non-codel (45) IDH-mut codel (39) IDH-wt (78) H-test P; r Post hoc
90% isocontour TTP 25 ± 8 23 ± 9 16 ± 8 < 0.001; 0.45 Δx
Slope15–40 − 0.2 ± 1.5 − 0.2 ± 1.0 − 1.1 ± 1.3 < 0.001; 0.44 Δx
TBR20–40 > 1.6 TBR5–15,max 3.3 ± 1.5 3.5 ± 1.7 4.2 ± 1.3 < 0.001; 0.37 Δx
TBR5–15,mean 2.0 ± 0.5 2.0 ± 0.5 2.4 ± 0.4 < 0,001; 0.45 Δx
TBR20–40,max 3.2 ± 1.2 3.2 ± 1.4 3.5 ± 1.1 0.060; 0.19
TBR20–40,mean 2.0 ± 0.3 2.1 ± 0.4 2.1 ± 0.3 0.074; 0.18
BTV20–40 21 ± 22 28 ± 32 26 ± 24 0.347; 0.11
PVHTBR,5–15 > 2 32 ± 27 32 ± 26 62 ± 23 < 0.001; 0.52 Δx
PVHTBR,20–40 > 2 33 ± 23 33 ± 25 41 ± 22 0.071; 0.18
PVHTTP > 30 47 ± 21 50 ± 18 23 ± 20 < 0.001; 0.57 Δx
PVHTTP < 15 12 ± 13 10 ± 9 34 ± 22 < 0.001; 0.56 Δx
PVHTTP < 20 26 ± 20 24 ± 14 56 ± 25 < 0.001; 0.58 Δx
PVHSlope < 0 27 ± 20 25 ± 14 55 ± 23 < 0.001; 0.58 Δx
TBR20–40 > 1.6, 10 mm Gauss PVHGaussTTP > 30 62 ± 30 67 ± 24 29 ± 28 < 0.001; 0.55 Δx
PVHGauss TTP < 20 17 ± 22 12 ± 13 50 ± 31 < 0.001; 0.56 Δx
PVHGauss,Slope < 0 21 ± 26 15 ± 16 56 ± 32 < 0.001; 0.57 Δx
Post hoc P < 0.05: +IDH-mut non-codel vs. IDH-mut codel, ΔIDH-mut non-codel vs. IDH-wt, xIDH-mut codel vs. IDH-wt
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negative slope (PVHSlope < 0) was slightly increased (not
significant) in WHO grade IV compared to that in
WHO grade III for IDH-mut non-codel gliomas. How-
ever, in the case of IDH-wt gliomas, the fraction of vox-
els with an early peak (PVHTTP < 20: P = 0.035, r = 0.29)
and negative slope (PVHSlope < 0: P = 0.010, r = 0.33) was
significantly higher in WHO grade III compared to that
in WHO grade IV gliomas. Simultaneously, PVHTBR,20–
40 > 2 was significantly higher in IDH-wt GBMs (P =
0.001, r = 0.42).
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Fig. 2 The upper row shows the average percentage volume fractions of the TTP (PVFTTP), i.e. the percentage portion of voxels with TTP in the
respective time frame. In the middle row, the corresponding cumulated histograms (PVHTTP) are presented, i.e. the percentage portion of voxels
with TTP below a certain value. The most significant differences between groups were found for PVHTTP < 20 (with the cut-off value TTP < 20 min
p.i. marked with red lines). The lower row depicts the boxplots of PVHTTP < 20. a IDH-mut non-codel. b IDH-mut codel. c IDH-wt
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The application of the exemplary Gaussian filter
(10 mm FWHM) yielded a comparable ability to differ-
entiate WHO grades and molecular genetic groups, as
reported in Tables 2, 3, and 4 and Additional file 1: Ta-
bles S1 and S2. However, a tendency of this spatial filter-
ing to reduce the fraction of voxels exhibiting an early
peak or negative slope was observed (Additional file 1:
Figure S1).
Spatial correlation of sub-volume fractions
The Sørensen-Dice coefficient, quantifying similarity of
the sub-volume fractions, was 0.72 between volumes
with TTP < 20 min p.i. and with negative Slope15–40, in-
dicating a high overlap of both properties. The
Sørensen-Dice coefficients of sub-volumes derived from
the static parameter TBR5–15 > 2 with sub-volumes de-
rived from kinetic parameters (TTP < 20 min p.i. or
negative Slope15–40) were 0.50 and 0.48. The corre-
sponding coefficients for the later TBR (TBR20–40 > 2)
sub-volume were 0.33 and 0.35.
Figure 5 shows the T1-weighted MRI images, TBR5–15
and TBR20–40 images, and parametric maps of TTP and
Slope15–40 for two typical WHO grade II gliomas (non--
codel and codel) and one IDH-wt WHO grade III glioma.
Additionally, an exemplary tumour with heterogeneous
pattern in parametric maps is displayed (classified by bi-
opsy as IDH-mut codel WHO grade II glioma), where the
maximum uptake in TBR images does not co-localise with
the hot-spot in early TTP and negative Slope15–40 images.
Discussion
In this study, we established an automated and reader-
independent method for voxel-wise 18F-FET PET glioma
analysis, which enables a fast identification of sub-vol-
umes consisting of voxels with aggressive high-grade
kinetics. By quantifying the intra-tumoural parameter
distribution with percentage volume histograms, we
found significant differences between WHO grades and
between molecular genetic groups. Both, association
with WHO grade and IDH mutation status, were higher
for PVH data compared to VOI-based parameters in
most cases. Interestingly, sub-group analyses showed
that in the special case of IDH-wt gliomas, the fraction
with early peak or negative slope was significantly higher
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Fig. 3 Data presented as in Fig. 2, with average percentage volume fractions of the slope (PVFSlope), the corresponding cumulated histograms
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in WHO grade III compared to WHO grade IV gliomas,
with simultaneously significantly higher PVHTBR,20–40 > 2
in WHO grade IV gliomas. Aggressive sub-volumes de-
fined by TTP < 20 min p.i. and negative Slope15–40
showed high overlap with each other, but a low overlap
with TBR5–15 > 2- and TBR20–40 > 2-defined hotspots, indi-
cating a possible complementarity of the investigated
kinetic and static parameters. The corresponding para-
metric images as presented in Fig. 5 may provide valu-
able information for a fast visual screening of glioma
tissue. In summary, this study demonstrates the rele-
vance and suitability of tumour heterogeneity assessment
on a voxel basis with static and kinetic 18F-FET PET pa-
rameters for a differentiated characterisation of gliomas,
although the clinical applicability of parametric 3D infor-
mation yet requires a comprehensive validation by utilis-
ing stereotactic biopsies.
In this context, an elaborate understanding of the
underlying processes of 18F-FET uptake is crucial and a
matter of current research [20, 31–35]. So far, various
studies suggest that regional information from static
18F-FET PET images and from MR-based morphological
and functional images is complementary, showing only
moderate overlap and low spatial correlation [36–39].
Still, tissue properties such as rCBV and rCBF might be
relevant for the delivery of 18F-FET, potentially influen-
cing 18F-FET uptake behaviour. rCBF was found to cor-
relate significantly with early slope (0–5 min p.i.) in
18F-FET PET and with TBR (20–40 min p.i.), however,
not with TAC patterns and late slope (10–50 min p.i.)
[40]. Recently, a negative correlation of rCBV and late
slope (10–30 min p.i.) and a positive correlation with
TBR (10–20 min p.i.) could be shown; however, only a
small fraction of the variance of early and late FET up-
take could be explained by rCBV [38]. Therefore, it was
concluded that rCBV and 18F-FET PET provide congru-
ent and complementary information on the underlying
processes. While late TBR may mainly reflect specific
trapping within tumour cells, the early TBR and the
TAC pattern may be influenced by rCBV and rCBF [38,
41]. Correlation of IDH mutation status with MRI pa-
rameters has among others shown that IDH-wt gliomas
tend to exhibit high rCBV values, which is a robust esti-
mate of tumour angiogenesis [32, 35]. In order to re-
trieve comprehensive information on the underlying
processes and their influence on 18F-FET uptake, further
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Fig. 4 Data presented as in Fig. 2, with average percentage volume fractions of the TBR (PVFTBR,5–15), the corresponding cumulated histograms
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investigations may combine information from PWI and
pharmacokinetic modelling with dynamic 18F-FET PET
data, also considering blocking studies.
Various studies were published evaluating thresholding
techniques optimised for the reproduction of true object
boundaries in PET images, possibly taking into account dif-
ferent image characteristics [42–45]. The currently estab-
lished method for BTV definition was verified with at least
one biopsy per patient, which was utilised for an optimisa-
tion of sensitivity and specificity and resulted in the optimal
TBR cut-off of 1.6 [15, 27]. As shown previously in mice, a
threshold relying on background and maximal uptake within
the tumour is superior for reproduction of histologically
proven glioma boundaries [46]. Hence, future studies consid-
ering glioma segmentation in humans, possibly further
including information from the characteristic kinetics of the
different glioma types, are desirable.
The proposed voxel-wise analysis including TTP and
Slope15–40 maps and percentage volume histograms of
static and kinetic parameters has the potential to provide
encompassing information not only for planning of bi-
opsy, surgery, or radiation therapy but also for progno-
sis, follow-up, and prediction of tumour recurrence
based on improved 3D information regarding the local
aggressiveness of tumour tissue. In this context, this
study has two limitations which need to be addressed in
future studies. Firstly, this work would benefit from a
correlation analysis of histopathologically assessed
tumour heterogeneity and the tumour heterogeneity in-
dicated by the proposed parametric 3D maps. Secondly,
Fig. 5 Contrast-enhanced T1-weighted MRI images of four example patients, and the corresponding parametric images of the early and late TBR,
the TTP, and the negative and positive Slope15–40 for the voxels within the BTV (zoom factor 2; BTV marked with white contour; TTP and Slope5–
15 images estimated from dynamic PET data smoothed with a Gaussian with 10 mm FWHM). a Images of three example patients with parameter
distributions characteristic of one IDH-mut non-codel WHO grade II glioma, one IDH-mut codel WHO grade II glioma, and one IDH-wt WHO
grade III glioma. b One example patient (IDH-mut codel WHO grade II glioma) with a mixed pattern in parametric images, where maximum
uptake in TBR images does not co-localise with the hotspot with early TTP and negative Slope15–40
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voxel-TACs are prone to noise in dynamic PET data, es-
pecially for shorter time frames. In this study, sensitive
parameters TTP and Slope15–40 were derived directly
from single-voxel TACs without the application of TAC
smoothing or fitting in order to avoid the introduction
of bias, i.e. change in temporal pattern, from TAC pre-
processing, and allow for an easy adoption by other re-
search centres. An exemplary simple method for
per-frame noise suppression with a spatial Gaussian fil-
ter was included and showed that PVH data changed
while the ability to differentiate glioma types was pre-
served, which further underlines the need for stereotac-
tic biopsies. Although the incorporation of a kinetic
model which is suitable to describe 18F-FET pharmaco-
kinetics seems conceivable, provided that appropriate
blood input data are available, voxel-based fitting of
complex models might also be sensitive to noise [19].
The presented data indicate the direct applicability for
non-invasive glioma grading and prediction of molecular
genetic profile. This is important, since the WHO classi-
fication was updated [26], and stratification is now based
on molecular genetic information, i.e. IDH-wt gliomas
are considered as having the same prognosis as glioblast-
omas themselves. A direct application is the clinical as-
sessment of lesions suspected of glioma, in particular for
the selection of the subsequent clinical steps such as bi-
opsy, resection, or “watch and wait”, but also for risk-
stratification in non-contrast-enhancing gliomas (IDH--
mut vs. IDH-wt). The next steps may further include
multi-parametric 3D analysis, machine learning ap-
proaches, the evaluation of the influence of small scale
motion on voxel-wise analysis, and the assessment of the
robustness of alternative methods for the voxel-wise
characterisation of gliomas, such as pharmacokinetic
modelling or the inclusion of information from other
imaging modalities like perfusion-weighted imaging.
Conclusions
Voxel-wise assessment of static and kinetic parameters
and partitioning of the entire tumour according to
voxel-wise properties enables an improved characterisa-
tion of glioma tissue, compared to VOI-based parame-
ters. Moreover, the 3D information might enable a fast
visual screening supporting the identification of aggres-
sive sub-volumes, thus guiding individual therapy instru-
mentation. The correlation between histopathology and
the impact on prognosis and prediction of tumour re-
currence needs to be evaluated in future studies.
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Figure S1 Exemplary voxel-wise TACs belonging to the glioma examples shown in Figure 5. a Voxel-
TACs with application of a Gaussian (10 mm FWHM) on dynamic PET data. b Original voxel-TACs 
without pre-processing of the dynamic PET data 
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